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ACETAMINOPHEN STIMULATES
PROLIFERATION OF BREAST CANCER CELLS
Eugenia Harnagea Theophilus
ABSTRACT
Acetaminophen is a common analgesic/antipyretic. This research projected investigated
the interaction of acetaminophen with breast cancer cells. The first goal was to determine
if acetaminophen induces proliferation in cancerous and normal, human breast cells.
Pharmacological concentrations of acetaminophen stimulated proliferation (3H-thymidine
incorporation into DNA, % S phase cells, cell numbers) of estrogen and progesterone
receptor positive (ER+/PR+) but not of ER-/PR+ or of ER-/PR- cancer or normal breast
cells. The second goal was to determine if estrogen receptors play a role in
acetaminophen-induced proliferation of ER+ breast cancer cells. Antiestrogens inhibited
acetaminophen-induced proliferation, suggesting that ERs are involved in proliferation.
However, acetaminophen did not bind to ERs in ER+ breast cancer cells, indicating that
while acetaminophen mimics some of estradiol effects, it does so by a different
mechanism. The third goal was to determine if the p-phenol moiety in acetaminophen
plays a role in the proliferation of ER+ breast cancer cells. The effects of the positional
isomers of acetaminophen on proliferation followed the order: p- > m- > o-
acetamidophenol. These findings indicate that the p-phenol is important for proliferation
of ER+ breast cancer cells. The fourth goal was to determine if metabolism of
acetaminophen occurs in breast cancer cells. Microsomes from ER+ breast cancer cells
that undergo proliferation in response to acetaminophen did not metabolize
acetaminophen to detectable levels except when cells were pretreated with inducers of
cytochrome P450. By contrast, ER- breast cancer cells metabolized acetaminophen to
detectable levels in both, cells non-induced and induced with cytochrome P450 inducers.
The fifth goal was to determine if acetaminophen affects tumor growth in nude mice
inoculated with ER+ human breast cancer cells. Acetaminophen (150 mg/kg/day), like
estradiol, stimulated tumor growth relative to negative controls up to day 36 following
inoculation with ER+ cells. However, after day 36, all tumors regressed. Taken together,
the data in this project are novel and help to understand the interaction of acetaminophen
with breast cancer cells, an area largely understudied.
iii
Dedication
To Paul, who enriches my life
iv
Acknowledgements
Special  thanks to Dr. Miller whose energy and enthusiasm inspired me and whose
great advice I will always remember. Thanks to Dr. Reasor for his incredible care and
valuable advice. Thanks to Drs. Strobl, Craig and Castranova for helping me with the
committee work. Thanks to Dr. Stamm whose competent input was always appreciated
and intellectually stimulating. Thanks to Doina Jickich who advised me to apply for this
graduate program. Thanks to my husband for all his help and support.
vTABLE OF CONTENTS
TITLE PAGE i
ABSTRACT ii
DEDICATION iii
ACKNOWLEDGEMENTS iv
TABLE OF CONTENTS v
TABLE OF FIGURES viii
CHAPTER I. INTRODUCTION 1
1. THE NORMAL AND CANCEROUS BREAST 1
1.1 General Aspects Related to the Normal and Cancerous Breast 1
1.2 Estrogen and Progesterone Regulation of Normal and Breast Cancer Cells 3
2. ESTROGEN AND PROGESTERONE RECEPTORS 7
2.1 Estrogen Receptors (ER) 7
2.2 Progesterone Receptors (PR) 11
3. MECHANISMS OF ER ACTION 14
3.1. Mechanism of Ligand-Dependent ER Activation 14
3.1.1. Estrogen Action 14
3.1.2. Antiestrogen Action 17
3.2. Mechanism of Ligand-Independent ER Activation 20
4. ENDOCRINE MODULATORS AND BREAST CANCER 24
4.1 Xenoestrogens 24
4.2 Estrogenic Drugs and Acetaminophen 28
4.3 Acetaminophen 29
vi
4.3.1 Physicochemical Properties 29
4.3.2 Dosage and Use 30
4.3.3 Acetaminophen Studies. Estrogenic/antiestrogenic activity 31
5. EXPERIMENTAL MODELS FOR STUDYING THE NORMAL AND
CANCEROUS BREAST 34
5.1 In Vitro Models 34
5.1.1 Breast Cell Cultures Advantages and Disadvantages 34
5.1.2 Normal Breast Cells in Culture 36
5.1.3. Breast Cancer Cells in Culture 37
5.2. In Vivo Experimental Models 40
6. RESEARCH PROJECT OBJECTIVES 42
CHAPTER II. MATERIALS AND METHODS 44
1. Materials 44
2. Methods 45
2.1 Cell Culture 45
2.2 Experimental Design 47
2.3 Endpoints in Vitro 48
2.4 Endpoints in Vivo 57
2.5 Statistics 58
CHAPTER III. RESULTS 59
3.1 Acetaminophen Effects on Breast Cancer Cells in Culture 59
3.1.1 3H-Thymidine Incorporation 60
vii
3.1.2 Percent S Phase Cells 65
3.1.3 Cell Numbers 67
3.1.4. Acetaminophen Induces 3H-Thymidine Incorporation under Other Dosing
Regimens 69
3.2. Cytotoxicity 71
3.3. Mechanisms of Acetaminophen-Induced Proliferation 71
3.3.1 T47D variants 71
3.3.2 Antiestrogen Studies 75
3.3.3 ER Binding Assays 83
3.3.4 Acetaminophen Isomers Studies 85
3.4 Metabolism Studies 88
3.5 In Vivo Data 90
3.6 Data Summary 92
CHAPTER IV. DISCUSSION 95
REFERENCES 115
CV 135
SIGNATURE PAGE 138
viii
LIST OF FIGURES
Figure 3.1. Chemical Structures of Selected Xenoestrogens and
of Acetaminophen ------------------------------------------------------------------------------- 59
Figure 3.2. Effects of Acetaminophen on 3H-Thymidine Incorporation into DNA in
estradiol-responsive (ER+/PR+) human breast cancer cells --------------------------- 60
Figure 3.3. Effects of Acetaminophen on DNA Synthesis in Estradiol-Nonresponsive
(ER-/PR-) Human Breast Cancer Cells ----------------------------------------------------- 63
Figure 3.4. Effects of Acetaminophen on DNA Synthesis in Normal Breast, ER-/PR-
HMEC cells --------------------------------------------------------------------------------------- 64
Figure 3.5. Effects of Acetaminophen on % S phase Cells in ER+ Human Breast
Cancer Cells -------------------------------------------------------------------------------------- 65
Figure 3.6. Effects of 0.1 mM Acetaminophen on T47D Cell Proliferation --------- 68
Figure 3.7. Acetaminophen Stimulates 3H-Thymidine Incorporation into DNA
under a 1 Dose/3 Days Dosing Regimen in MCF7 Cells and T47D Cells but not
under a 1 Dose/1 Day Dosing Regimen in MCF7 Cells ---------------------------------- 70
3.8. Effects of Acetaminophen on T47Dco, T47DYA and T47DYB Cells ----------- 73
Figure 3.9. Effects of ICI 182780 on Acetaminophen and Estradiol-Induced % S
Phase MCF7 Cells ------------------------------------------------------------------------------- 76
Figure 3.10. Effects of 4-Hydroxytamoxifen on Acetaminophen and Estradiol-
Induced % S Phase MCF7 Cells-------------------------------------------------------------- 77
Figure 3.11. Effects of ICI 182780 on % S Phase MDA-MB-231 Cells -------------- 78
ix
Figure 3.12. Effects of ICI 182780 and 4-Hydroxytamoxifen on Acetaminophen-
Induced MCF7 Cell Proliferation------------------------------------------------------------ 80
Figure 3.13. Effects of ICI 182780 and 4-Hydroxytamoxifen in Acetaminophen-
Induced T47D Cell Proliferation ------------------------------------------------------------- 82
Figure 3.14. Acetaminophen does not Compete with Estradiol for Binding Estrogen
Receptors in MCF7 Cells ---------------------------------------------------------------------- 84
Figure 3.15. Effects of Acetaminophen Positional Isomers on T47D and MCF7 Cell
Proliferation -------------------------------------------------------------------------------------- 86
Figure 3.16. Acetaminophen metabolites from breast cancer cells microsomes --- 89
Figure 3.17. Acetaminophen Stimulates MCF7 Tumor Growth in Nude Mice ---- 90
1CHAPTER I. INTRODUCTION
1. THE NORMAL AND CANCEROUS BREAST
1.1 General Aspects Related to the Normal and Cancerous Breast
        This project deals with breast cancer models. Therefore, some background is provided about
the anatomy and physiology of the breast, and a classification of types of breast cancer according
to their anatomical origin is included as well. Under normal circumstances, the breast in females
fulfills vital functions in infant nutrition. The breast is located in the hypodermis of the anterior
thoracic wall and consists of 15 to 20 lobes of glandular tubuloalveolar tissue, fibrous connective
tissue connecting the lobes, and adipose tissue between  the lobes. The epithelium is organized as
a branching duct system terminating, when fully developed, in secretory ductules and alveoli.
Subcutaneous fat and adipose tissue account for most of the breast mass in the non-lactating
state. When the normal breast undergoes abnormal changes in physicochemical composition,
structural, and functional changes,  various diseases of the breast can result, including cancer. For
example, many cancers involve abnormalities of ducts and alveoli. Accordingly, some breast
cancers are classified according to their origin in the breast as ductal or lobular, and according to
their invasive potential as noninvasive or invasive. While 80% of breast carcinomas are ductal
invasive, intraductal carcinomas constitute 10-15%, lobular, 5-7%, and special types, 3-5%.
Models of breast cancer used in this study represent some of the most frequently encountered
2types of breast cancer.
       Breast cancer is thought to be a multi-factorial disease, involving genetic, environmental,
hormonal, and dietary factors, but its precise etiology is not known. While known risk factors can
account for certain breast cancers, most are caused by yet undetermined factors. Models of breast
cancer development propose that series of genetic changes contribute to the dynamic process of
carcinogenesis (Boone et al., 1993) and accumulation of genetic changes is thought to participate
in the evolution of malignancy. The carcinogenesis sequence is viewed as starting with tissue of
normal appearance, followed by changes that lead to hyperplasia and dysplasia, with the most
severe forms being difficult to distinguish from carcinoma in situ (Keloff et al., 1994). Some of
the main forces driving the carcinogenic process have been characterized as mutagenesis and
mitogenesis. If cancer escapes control, advanced metastatic stages often lead to death. Despite
better means of preventing and treating breast cancer, one in eight US women will still develop
breast cancer during her lifetime (Feuer et al., 1993). In fact, mortality rates from breast cancer
are second only to lung cancer. Given these considerations, it is important to better understand
the dynamics of aberrant proliferation involved in breast cancer.
31.2 Estrogen and Progesterone Regulation of Normal and Breast Cancer Cells
        Sex steroid hormones include estradiol and progesterone, and these hormones regulate
normal breast cells and some cancerous breast cells that have both estrogen and progesterone
receptors (ER+/PR+). Normal physiologic processes regulated by estrogen and progesterone
include reproduction, embryo maturation, and sexual differentiation. These hormones can also
affect some pathological processes, including some breast cancers. Because we have used
estradiol as a positive control in our studies of normal and breast cancer cells, some background
regarding how estradiol regulates breast cells under normal circumstances is given below.
       Synthesis. The major estrogens produced by women are estradiol (most abundant and
potent), estrone, and estriol. Estrogens are produced by females primarily in ovaries and by males
primarily in testes. While the ovary is the primary source of estradiol in premenopausal women,
the adrenal gland can synthesize estrogens in postmenopausal women and in men. Other
estrogen-producing tissues include fat, hair follicles, liver and skeletal muscle. These tissues
convert circulating androstenedione and testosterone (secreted by testes) into estrogens.
       The other hormone that can act in concert with estrogen to regulate estrogen-responsive cells
in vivo is progesterone. Progesterone is the most important natural progestin. Like estrogen,
progesterone is produced in both females and males. In females it is secreted by corpus luteum
4primarily during the second half of the menstrual cycle and by placenta. In males testes secrete
progesterone. It is also synthesized by the adrenal cortex in both sexes.
       Both estrogen and progesterone are synthesized from cholesterol precursors with
progesterone preceding estrogen formation in the synthetic path. A variety of enzymes catalyze
these synthetic reactions. Synthesis and release are regulated by the hypothalamus-pituitary axis.
Gonadotropin releasing hormone (GnRH) from the hypothalamus regulates release of leutinizing
hormone (LH) and follicle stimulating hormone (FSH) from anterior pituitary which in turn
regulate sex hormones that feedback at the level of hypothalamus or pituitary. Sex steroids are
metabolized by liver and other target organs and are excreted as conjugates via kidney and to a
lesser extent via intestines.
       Plasma estradiol levels. In our studies 3nM estradiol was used as positive control. These
levels correspond to ~816 pg/ml and reflect physiologic levels of estradiol achieved during early
stages of pregnancy. To provide context for how these estradiol levels compare to estradiol levels
during other stages of a woman’s life, a more detailed description of estradiol level fluctuation
with age is included below. In girls before 9-10 years of age, plasma estradiol levels are
approximately 5 pg/ml (Berne and Levy, 1993). With onset of puberty, between ages 11-15, as
ovarian secretion commences, budding of breasts coincides with increases in plasma estradiol
levels to approximately 50 pg/ml (Berne and Levy, 1993). During ages 13-15, plasma estradiol
5levels rise to approximately 120 pg/ml (Berne and Levy, 1993). In premenopausal women
estradiol levels are as follows: during the early follicular phase, ~50 pg/ml, late follicular phase,
350-500 pg/ml, and middle luteal 200 pg/ml (Berne and Levy, 1993). During pregnancy,
estradiol levels increase to ~16 ng/ml at the end of pregnancy. At menopause estradiol levels
become ~10-20 pg/ml (Berne and Levy, 1993).
       Effects. In general, the effects of sex hormones are strictly dependent on life stage and cell-
type. Production of estrogens and progesterone by ovaries at puberty stimulates initial growth of
mammary gland. Estrogen stimulates proliferation of ductal epithelial, myoepithelial and stromal
cells of the breast. Progesterone together with estrogen initiates formation of secretory acinar
components at distal aspects of ductules. With menarche, the cyclical estrogen and progesterone
increase and further stimulate proliferation of ducts and formation of lobules. Progesterone and
estrogen also stimulate proliferation of connective tissue that subsequently replaces adipose
tissue and provides support for the developing ducts. In addition, ovarian steroids stimulate
proliferation of adipose tissue and enhance proportional enlargement and pigmentation of areola.
During pregnancy, the mammary glands undergo dramatic proliferation and development.
Placenta and corpus luteum continuously increase overall estrogen and progesterone levels
further stimulating proliferation and breast development. Alveolar development becomes
prevalent, then cell proliferation ultimately declines and alveolar hypertrophy replaces
proliferation. After menopause, mammary glands involute. The secretory cells of alveoli and
connective tissue eventually degenerate, and stromal cells and collagen fibers decrease in
6numbers.
       Estrogens are stimulatory not only to the normal breast at specific developmental stages but
also to some breast cancer cells. Moreover, estrogenic hormones may play multiple roles in
neoplastic progression as carcinogens, and as growth promoters. For example, estrogens are
known to favor DNA damage through promotion of free radicals and, thus, may be involved in
tumor initiation (Ciocca and Fanelli, 1997). But they have been mainly implicated in tumor
promotion because of their mitogenic/proliferative activity (Ciocca and Fanelli, 1997). Normally,
target breast cells have proper negative feedback control such that estrogenic stimulation does
not promote carcinogenesis. However, increased exposure to estrogens/xenoestrogens increases
the likelihood that normal cellular controls become altered (Ciocca and Fanelli, 1997).
72. ESTROGEN AND PROGESTERONE RECEPTORS
2.1 Estrogen Receptors (ER)
      Some breast cancer cell types used in these studies contain estrogen and progesterone
receptors (ER+/PR+ cells). These cells include MCF7, T47D, and ZR-75-1 cells. Other types of
breast cancer cells used in these studies, for example MDA-MB-231 cells, are classified as ER-
/PR- cells. Therefore, some background about ERs and PRs is given below. Two main ER
subtypes have been described:  the classical receptor and  only recently reported (Kuiper et
al., 1996 and Mosselman et al., 1996). At a subcellular level, ERs are found predominantly in
nucleus but also in cytoplasm and membranes. At tissue level, some estrogen-responsive tissues
contain only , others only  and yet others, both subtypes (Kuiper et al., 1997). It is possible
that different tissue distributions of ERs as well as homo- or hetero-dimer formation may account
for different types of regulation and tissue/cell-specific functions.
       In the ER+/PR+ cells used in these studies, both ER and ER are present. More is known
about the classic ER than about the newly discovered ER ER is a 66-kDa protein composed
of 595 amino acids. It has 6 structural domains (A at the NH2 terminus through F, at the COOH
terminus). Domain A spans amino acids 1-38; B, 38-180; C, 180-263; D, 263-302; E, 302-553;
F, 553-595. The ER has two activation functions, AF1 in domain B and AF2 in domain E. In
most estrogen-responsive cells, AF1 and AF2 function synergistically to activate estrogen-
8responsive gene transcription induced by pure agonists. Partial agonists/antagonists generally use
only one of these activation functions (Katzenellenbogen et al, 1997). However, depending on
the cell context and type of ligand/signal, AF1 and AF2 may act synergistically or independently
(Smith, 1998) and so, the activities of AF1 and AF2 vary with cell type. Furthermore, AF1 is
considered the basal activation function, while AF2 found in the ligand binding domain is
considered ligand-inducible (Smith, 1998). The DNA binding domain (C) has two Zn fingers in
which cysteine residues are coordinated to Zn ions. Region D is involved in binding chaperone
proteins and in nuclear recognition. Region E is involved in ligand binding, heat shock protein
binding, dimerization, and transcription activation (AF2 function). The last domain, F, modulates
transcriptional activation (Smith, 1998).
       ERs are regulated in part by changes in phosphorylation. The ER receptor is a
phosphoprotein that has 5 critical phosphorylation sites Ser 104, 106, 118, 167 and Tyr 537
(Smith, 1998). Mutations in these phosphorylation sites can modulate transcriptional activity of
ER, thwarting receptor function (Smith, 1998).
       ER  and  are differentially distributed in various estrogen-responsive tissues, suggesting
different organ-specific roles for different combinations of ER subtypes. The distribution of ERs
in humans is consistent with that in animals. For example, human ER was detected in testes
(seminiferous epithelium, developing spermatids, stroma of cortex, blood vessels of medulla),
9prostate (epithelium of secretory alveoli), ovary (granulosa cells in humans have only ), and
uterus (Bhat et al., 1998; Enmark et al., 1997; Mosselman et al., 1996). In addition, studies
conducted in midgestational human fetus by Brandenberger et al. (1997) have shown that mRNA
for ER was most abundant in uterus, and less abundant but present in ovaries, testis, skin, and
gut. Levels of ER were higher than levels of ERmRNA in fetal ovaries, testes, adrenals and
spleen. In uterus, ER levels were higher than ER mRNA levels. ER mRNA was moderate to
low in thymus, pituitary, skin, lung, kidney and brain cortex of midgestational human fetus
(Brandenberger et al., 1997). The presence of ERs of either one or both subtypes in these tissues
is believed to reflect distinct physiologic functions of these receptors within those tissues.
However, such functions are not completely understood.
       While it was known for some time that the classic ER is important in physiologic processes
regulating the normal breast and in breast cancer, with the discovery of ER a possible role for
ER in human breast cancer and in other cancers has emerged as well. For example, Pedeutour et
al. (1998) noted that the human ER gene is located in a region frequently rearranged in uterine
leiomyomata and other benign tumors, including pulmonary chondroid hamartomas and
endometrial polyps, suggesting a potential role for ERin these diseases. Other researchers
(Enmark et al., 1997) noted that regions of chromosome 14 are also rearranged in kidney
neoplasms and genes involved in early onset of Alzheimer’s disease. Dotzlaw et al. (1997) and
Lu et al. (1998) detected ERin several human breast tumor biopsies and several human breast
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epithelial cells. Consistent with the studies just described, Vladusic et al. (1998) identified ER
in some breast tumors and cells. For example, a variant of ER is coexpressed with wild-type
ER in the ER-/PR- human breast cancer cell line MDA-MB-231 and in malignant breast
tumor specimens. This variant, however, was not detected in the tested normal breast tissue. The
ER variant had 139 bp deleted in the hormone-binding domain, corresponding to exon 5 of
ER. The ER variant protein was predicted to lack part of the hormone-binding domain and to
bind estradiol with lower affinity than the wild-type ER protein.
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2.2 Progesterone Receptors (PR)
       Breast cancer cells with various complements of ER and PR were used in this study to
differentiate between acetaminophen-induced effects mediated by ER and by PR. PR exhibits
properties and functions different from ER as briefly discussed below. Unlike the ER, a single
gene located on chromosome 11 (Graham et al., 1989) encodes two forms of PRs, designated
PRA and PRB. Like ERs, the distribution of PRs varies and some tissues/cells express only one
isoform or both. For example, in uterine fibroids PR levels are higher than in adjacent normal
tissue (with PRA greater than PRB). In addition, a significant number of tumors have high PRA
and low PRB levels. And, as with ERs, PRA and PRB vary with life stage and menstrual cycle.
For example, both isoforms are expressed highly in the periovulatory phase of the cycle with
PRA higher than PRB. Moreover, PRB is maximally expressed during days 14-16 of menstrual
cycle and minimally expressed at beginning and end of cycle. PRA  (94 kDa) is an N-terminally
truncated form of PRB which exists as triplets (114, 117, and 120 kDa) (Sheridan et al., 1989;
Keightley, 1998). When analyzed by Western blotting, PRs are initially seen as single B bands of
114 kDa and a single A band of 94 kDa (Sheridan et al., 1989). The mature B-triplets seen as
three bands on Western blots form 6-10 h later by post-translational phosphorylation at sites
restricted to the B-proteins (Sheridan et al., 1989). This slow maturation is not required for PR
activation to hormone binding states, however, since A- and B-receptors less than 15 min old
respond to progestins by undergoing transformation and nuclear binding accompanied by a rapid
secondary phosphorylation common to both proteins (Sheridan et al., 1989). The two isoforms
differ functionally when occupied by agonists or antagonists, and the unique 164-amino acid, B-
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upstream segment (BUS) is in part responsible for the functional differences between the two
isoforms (Sartorius et al., 1994). The B-isoform of human progesterone receptors contains three
activation functions (AF3, AF1, and AF2), two of which (AF1 and AF2) are shared with the A-
isoform (Hovland et al. 1998). AF1 is located in the N terminus in a 90-amino acid segment just
up-stream of the DNA-binding domain (DBD) and nuclear localization signal (NLS), and AF2 is
located in C terminus in the hormone-binding domain. BUS is a highly phosphorylated domain,
and contains the serine residues responsible for the PRB triplet protein structure. AF3 in PRB is
located within BUS and requires a functional DBD. Depending on the promoter or cell tested,
AF3 can activate transcription autonomously, or it can functionally synergize with AF1 or AF2.
Autonomous AF3 function may explain the unexpected transactivating actions of antiprogestin-
occupied PRB, an issue of importance in hormone-resistant breast cancers and in tissue-specific
agonist-like effects of hormone antagonists. B-receptors are usually stronger transactivators than
A-receptors due to transcriptional synergism between AF3 and one of the two downstream AFs
(Hovland et al., 1998). Nevertheless, both forms bind progesterone and are transcriptionally
active (Vegeto et al., 1993). However, PRA expression is dominant over PRB (Keightley, 1998).
       Like in the case of ERs, phosphorylation is a major means of regulating PRs. Human
progesterone receptors (PRs) are phosphorylated at multiple serine residues basally; they become
hyperphosphorylated by hormones (Takimoto et al, 1992). Compared to PRA, PRB contains
three extra phosphorylation sites in its N terminal domain (Zhang et al., 1994), one of which is
phosphorylated by casein kinase on Ser 81 (Zhang et al., 1994) and the other on Ser 162 (Zhang
13
al., 1997).
       Since PRB has been known long before ERbeta, the importance of homo and heterodimer
formation in PR action has long been recognized. Like ERs, PRs can exist as hetero or
homodimers and there are specific cell types that express only PRA, only PRB homodimers or
PRA-PRB heterodimers. Both ER and PR DNA binding involve dimerization in most cases but
PR transformation also involves dissociation and unmasking of A subunit with greater DNA
affinity. In both ER and PR action, the pattern of transcriptional activation depends on the
particular combination of homo/heterodimer receptor complexes. Liganded PRA and PRB can
suppress estradiol-stimulated ER activity and PRA also suppresses PRB (so, PRA is a stronger
repressor). The magnitude of PR suppression of ER response depends on which PR isoform is
predominant and cell type (Katzenellenbogen, 1996). PRB under certain conditions can switch
from recognizing an antagonist as an antagonist to mis-recognizing an antagonist as an agonist.
In contrast, PRA does not display such undesired switch activity and strongly represses not only
PRB but also other members of the steroid receptor family such as androgen receptors and
glucocorticoid receptors (Vegeto et al., 1993). Liganded PRA and PRB can each suppress
estradiol-stimulated ER activity with the magnitude of repression dependent on the PR isoform,
progestin ligand, promoter, and cell context/type (Katzenellenbogen, 1996). The clinical
relevance is that in ER+/PR+ tissues antiprogestins (e.g., RU486) can antagonize not only the
PRB-mediated transactivation but also ER-mediated transactivation via PRA inhibition of ER
(Keightley, 1998).
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3. MECHANISMS OF ER ACTION
3.1. Mechanism of Ligand-Dependent ER Activation
3.1.1. Estrogen Action
       The mechanism of both estrogen and antiestrogen action involve ERs. The phosphorylated
ERs can function as inducible, ligand dependent or independent transcription factors. ER
function appears to be controlled by two key regulators: (1) cell cycle specific and nonspecific
kinases and phosphatases that dictate critical phosphorylation changes and (2) Hsp90
heterocomplex/transcriptional complexes (Katzenellenbogen et al., 1996; Weigel and Zhang,
1998; Lieberman, 1997).
       ERs undergo activity cycles. According to Lieberman (1997), a cycle includes several steps.
(1) ER associates with Hsp90 (ER priming). (2) Hsp90 heterocomplex dissociates from ERs
followed by release of dimers or release of monomers with subsequent dimerization. (3) ERs are
transported to nucleus. (4) If ligand is present, it binds the ER; then Zn fingers become exposed
and the ER-ligand binds the DNA estrogen response element directly or indirectly, via other
nuclear proteins such as SP1 proteins or SRC-1, ERAP, or A1B1 coactivator proteins. (5)
Estrogen-responsive gene transcription occurs. (6) ERs dissociate from the transcription
machinery. (7) ERs reassociate with the Hsp90 heterocomplex, then deactivate and degrade
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(Lieberman, 1997). In target cells, during step 1, Hsp90 heterocomplexes block inappropriate
ER-DNA interactions and at the same time prime ERs for incoming signals, helping them to
become functional once signal has reached its target. ER-ligand complexes then become
hyperphosphorylated, and complete step 3, moving to the nucleus, aided by Hsp70. They reach
the nuclear membrane, Hsp70 dissociates and ligand-ER complexes enter into the nucleus. Step 3
in the classical mechanistic model involves ER dimerization that must occur for ER to complete
step 4 (DNA binding); however, there are also reports of ERs binding as monomers or multimers
(Lieberman, 1997). During step 4, ligand binds to ER. Occupancy of 5 % of the total ER
population is sufficient for strong agonists, such as 17 estradiol to increase estrogen-dependent
gene transcription and cell proliferation (Ciocca and Fanelli, 1997). ER-ligand complexes can
bind to a transcriptional complex made of nuclear protein and bind indirectly to the estrogen
response element on DNA. Alternatively, the ER-ligand complex can bind directly to the DNA
response element (Lieberman, 1997) and some papers indicate that nuclear Hsp90 also
contributes to DNA binding (Inano et al., 1994). Two DNA Zn fingers participate in dictating the
association of the ER with the estrogen response element of specific genes. As mentioned,
interaction of ER with the estrogen response element can occur either directly or indirectly,
mediated by transcriptional complexes (Katzenellenbogen et al., 1997). Subsequent to ligand
binding, ligand-ER complexes change conformation and dissociate from Hsp90 in cytoplasm or
nucleus (not known). Further, depending upon whether the ligand is an agonist or an antagonist
and depending upon concentration, step 5 ensues with activation or suppression of estrogen-
responsive gene expression (e.g., PR gene induction). The net effect is increased/decreased
protein product (e.g., PR protein) and stimulation/suppression of proliferation
16
(Katzenellenbogen, 1997). One cycle ends with step 7, culminating in ER degradation and a new
cycle begins with ER resynthesis.
       The most potent estrogen, 17 -estradiol, initially upregulates both ER and PR synthesis,
then high PR levels downregulate both ER and PR by mechanisms not well understood. It has
been suggested that long-term (days) exposure of ER+ cells to agonists leads to activation by
ligand of both the ligand-dependent and the ligand-independent pathways (Castaño et al., 1998).
This occurs because long-term agonists can stimulate production of growth factors, e.g.,
epidermal growth factor (EGF), transforming growth factor  (TGF insulin-like growth factor
(IGF-I) and their receptors (Smith, 1998). The cells, in turn, exert positive feedback on
themselves or neighboring cells and activate the MAP kinase pathway. Alternatively, estradiol
may simply act on membrane receptors (Castaño et al., 1998).  Thus, the mechanism of ER
activation is complex and complexity is added in cells like the ER+ breast cancer cells used in
this research in which ER coexists with ERor in cells with only ER
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3.1.2. Antiestrogen Action
        Antiestrogens are used in both clinical (for example for treatment of breast cancer) and in
experimental situations to determine if compounds with estrogenic activity act via ERs.
Antiestrogens are traditionally known to compete with estrogen for binding to ERs and, thus,
block estrogen-responsive gene transcription and cell proliferation. However, there is more to
antiestrogen action than this simplified mechanistic view. This will be considered in more detail
in the next section. In this section some aspects that distinguish partial from complete
antiestrogens are considered. The mechanisms of action of partial and complete antiestrogens
have similarities and differences. For example, both partial (e.g., tamoxifen) and complete (e.g.,
ICI 182,780) antiestrogens induce changes in the conformation of the ER. However, only
complete antiestrogens also decrease the levels of ERs by decreasing receptor half-life and
increasing receptor degradation (Katzenellenbogen et al., 1997). It is interesting to note that a
chemical that appears to act in a similar manner (by changing steroid receptor conformation and
increasing its degradation) is geldanamycin. This compound specifically inhibits Hsp90
heterocomplex function and thus the function of the steroid receptors associated with it (Neckers
et al., 1998). Such a parallel suggests that the Hsp90 heterocomplex or other ER interacting
proteins may be additional/alternative targets of pure antiestrogens. For example, ICI182780
alters or blocks the stress pathway via MAP kinase, and blocks Ser 118 phosphorylation of ER
(Castaño et al., 1998). This may occur by ICI 182780 interfering with the dissociation of
accessory proteins blocking access of MAP kinase to this site (Castaño et al., 1998). Thus,
antiestrogens such as ICI182780 are more effective than tamoxifen because they block the
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receptor, like tamoxifen, leading to decreased transcription activation, but they may also
destabilize the interaction of ER with critical regulatory proteins involved in transcription
regulation and in ER proteolysis, such as the Hsp90 heterocomplex. Such events involve
increased receptor turnover due to impaired dimerization that results in impaired function of ERs
(DeCupris and Favoni, 1997). Another difference between partial and complete antiestrogens is
that, in contrast to partial antiestrogens, complete antiestrogens have a higher affinity for ERs,
being up to 100 fold more potent than tamoxifen (DeCupris and Favoni, 1997).
     Many compounds that mimic estrogen action or inhibit it, bind to ERs but the affinity of
various agonists and antagonists that bind to the different ER subtypes varies. Some examples
included binding profiles of antiestrogens used in the studies described in this dissertation are
summarized below. Initially, it was reported that ER transactivation by 17 -estradiol is similar
to ER and that the ER antagonist, ICI-164384 is a potent antagonist for ER as well
(Mosselman et al., 1996). Subsequently, some differences were noted between the binding
affinities of ligands to the different ERs (Kuiper et al., 1997). For example, the affinity for 17
estradiol of ER was reported to be slightly lower than for ER with Kd = 0.5 nM and Kd=
0.2 nM, respectively (Tremblay et al., 1997; Kuiper et al., 1998). Consistently, antiestrogens like
4-hydroxytamoxifen, ICI182780, and EM-800 inhibited estradiol-dependent transactivation in
other studies (Tremblay et al., 1997). However, 4-hydroxytamoxifen displayed partial agonistic
activity with only with ER not with ER (Tremblay et al., 1997). Other studies indicated that in
rat the affinity of 17 estradiol for ERsubtypes varied, with Kd2 = 5.1 nM; Kd = 0.19 nM;
19
and Kd1 = 0.14 nM (Petersen et al., 1998). In addition, all known estrogenic agents, including
physiological estrogens (estrone and estriol), plant and environmental estrogens (genistein,
coumestrol, bisphenol A, methoxychlor), and pharmacological agents (tamoxifen, 4-
hydroxytamoxifen) competed with estradiol for binding to both ER1 and ER2. However,
differences between ERsubtypes were found. For example, genistein bound preferentially to
ER1 compared to ER2 (Petersen et al., 1998). In contrast, 4-hydroxytamoxifen bound equally
well to both receptors (Petersen et al., 1998). Barkhem et al., 1998 confirmed that some
compounds prefer to bind to ER over ERor vice versa while others can bind to both to ER
and ER equally well. For example, 17-ethynyl 17-estradiol, has an ER-selective agonist
potency while 1617-epiestriol has an ER-selective agonist potency. Genistein has ER-
selective affinity and potency but ER-selective efficacy. Tamoxifen, 4-OH-tamoxifen,
raloxifene, and ICI 164384 are partial agonists/antagonists at ER but pure antagonists at ER.
In addition, raloxifene displayed ER-selective antagonist potency, in agreement with its ER-
selective affinity. However, although ICI 164384 showed ER-selective affinity, it had a similar
potency to antagonize the effect of 17-estradiol in both ER- and ER-specific reporter cell
lines. These data suggest that ER and ER have different ligand binding profiles depending on
whether the ligand is a partial or total agonist/antagonist.
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3.2. Mechanism of Ligand-Independent ER Activation
       Alternative ligand-independent mechanisms of ER activation are relatively newly
recognized. Thus, much less is known about it than about the classical ligand-dependent
activation of ERs. Ligand-independent transcriptional activation is dependent on cell type, on ER
type (wild type or mutant), the complement of proteins present in a certain cell-type, co-
repressors/co-activators, and the effects of signal transduction on levels and interactions of these
proteins. A variety of signals such as growth factors (epidermal growth factor, EGF; insulin
growth factor, IGF-1; Her2/neu), neurotransmitters (dopamine), second messengers (cAMP) and
stress, can act via membrane receptors and can activate ERs in turn (Katzenellenbogen et al.
1997; Castaño et al., 1998). For example, dopamine or dopamine agonists stimulate ER-
dependent gene transcription by acting on D1 receptors in plasma membrane (Smith, 1998).
Other examples include protein phosphatase inhibitors, such as okadaic acid, or PKA activators,
such as chlolera toxin that can ligand-independently stimulate ER-mediated transcription (Smith,
1998). Thus, in absence of ligand, agents that act on ER regulatory enzymes and that specifically
activate protein kinases or inhibit protein phosphatases can stimulate ER-dependent gene
transcription (Smith et al., 1998). In addition, estradiol and protein kinase activators can
synergistically stimulate ER-mediated transcription. This occurs by interaction with target
components of transcriptional complexes via phosphorylation changes or via interactions with
proteins that modulate ER during transcriptional activation (Katzenellenbogen, 1996). Additional
examples include growth factors that can activate ERs by pathways that cross the ER pathway.
For example EGF acting through its own receptors in cell membranes can activate ERs.
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Transforming growth factor alpha, TGF, cAMP and IGF-1 actions can be mediated by ERs as
well (Weigel and Zhang, 1998, Lee et al., 1999).
       The ER can also become ligand independent in certain circumstances. For example,
mutations at critical residues and partial to total deletion of the hormone-binding domain (thus
the AF2 activation function) can render ERs constitutively active. This suggests that only the
AF1 is required for ERs to have constitutive action or action induced by growth factor signaling
cascades.
       As mentioned before, the ability of the receptor to induce transcription depends in part on the
proteins with which the receptor interacts to induce transcription. It has been pointed out that two
key regulators of this process are enzymes affecting phosphorylation changes and Hsp90
heterocomplexes. In the ligand-independent pathway, the growth factor (e.g., EGF) binds to its
plasma membrane receptor, activates the MAP kinase cascade, and induces phosphorylation of
Ser 118 on the ER. This facilitates ER transport to the nucleus and ER binding to transcription
factors instead of binding directly to ERE, as occurs in the ligand-dependent case. This sequence
leads to similar subsequent events as described in the ligand-dependent activation such as DNA
and protein synthesis and proliferation (Castaño et al., 1998; Katzenellenbogen et al., 1997).
These types of differences are thought to potentially account in part for the observed mixed
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agonist/antagonist activity of antiestrogens such as tamoxifen.
       Antiestrogens can inhibit some ER-independent pathways as well. For instance,
antiestrogens can block some growth factors that exert autocrine positive feedback on cell
proliferation (Katzenellenbogen et al., 1997). They may also block some growth factor receptors
(TGF, IGF-I) while they induce growth inhibitory factors (TGF) and their receptors
(Katzenellenbogen et al., 1997; DeCupris and Favoni, 1998). Some clinical antiestrogens such as
tamoxifen are partial antagonists/agonists and, consequently, depending on cell type, they can act
as antagonists in breast cancer cells but as agonists in endometrial cells and, thus, produce side
effects (endometrial cancer). Additional effects of antiestrogens include inhibition of
angiogenesis, induction of apoptosis and increase in tumor suppressor protein products of genes
such as BRCA1 (Katzenellenbogen et al., 1997). Tamoxifen can also affect cellular function by
binding to calmodulin or inhibiting PKC (DeCupris and Favoni, 1997). So, antiestrogens can
inhibit cell growth and induce apoptosis independently of the ER in both ER+ and ER- breast
cancer cell lines (DeCupris and Favoni, 1997).
       One of the main differences between the ligand-dependent and ligand-independent activation
is thought to be the differential phosphorylation of critical residues on ERs, with ligand-
dependent activation leading preferentially to Ser 167 phosphorylation while ligand-independent
phosphorylation involving Ser 118 phosphorylation (Castaño et al., 1998). However, whether
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such clear differences exist is still unclear (Weigel and Zhang, 1998). Furthermore,
phosphorylation of Tyr 537 has also been implicated in ligand-independent activation of ER,
especially in steps such as the release of Hsp90 from ERs (Castaño et al., 1998). Mutations in Tyr
537 create constitutively active ERs and in contrast to wild type ERs, these mutants can interact
with coactivator proteins, such as SRC-1, in the absence of hormone. Thus the Tyr 537 and the
adjacent amphipathic helix form a conformation-dependent interaction surface for coactivators
(Smith, 1998). Tremblay et al. (1998) found, consistently, that mutations at Tyr 537 in ER and
at Tyr 443 in ER rendered constitutively active ERs. However, the ligand-independent
transcriptional activity of all ER and ER mutants examined, was completely abolished by
antiestrogens (EM-652, ICI 182,780, and 4-hydroxytamoxifen). Thus, a compound could mimic
estradiol effects by altering for example ER phosphorylation, without actually binding ERs and
antiestrogens would inhibit these estrogenic effects even though they are not directly mediated by
binding to ERs.
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4. ENDOCRINE MODULATORS
4.1 Xenoestrogens
       Xenoestrogens (also called estrogens, estrogenic xenobiotics, endocrine activators,
modulators, or disrupters), are exogenous chemicals that modify normal estrogen functions in the
body (Raloff, 1993). The definition of estrogenic chemicals is highly controversial mainly
because many xenoestrogens are not total mimics of estrogen action but partial mimics or mimics
of one or more but not all of estrogen responses. Xenoestrogens have stimulatory effects in
various tissues. Stimulatory effects are direct effects manifested by xenoestrogens in estrogen-
responsive, target tissues and cells by mimicry of estrogen actions. Normally, like estrogen
(particularly estradiol, the main estrogen) xenoestrogens are able to induce the proliferation of
different cells that are components of estrogen target organs. For example, proliferation can
occur in lobular ducts and adipose tissue in breasts, in endometrium in uterus, in secretory
epithelial and ciliated cells in fallopian tubes, or in squamous epithelial cells in vagina (Berne
and Levy, 1992). Other stimulatory effects of xenoestrogens that mimic estrogen effects include
induction of increased secretion of various proteins in breast, uterus, liver, and increased Na+
reabsorption in kidneys that leads to increased water retention in cervix (Berne and Levy, 1992).
Absence or depletion of estrogens and xenoestrogens or presence of antiestrogens leads to
inhibitory effects in estrogen-responsive tissues and cells. For example, depletion of estrogen at
menopause leads to bone loss (Vorherr, 1967). Overall, estrogenicity is the capacity of a
xenoestrogen to induce estrogenic effects.
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       Xenoestrogens are derived from various sources and can have different effects on different
reproductive tissues. Natural xenoestrogens include plant components (e.g., genistein),
mycotoxins (e.g., zeranol), or microbial intestinal faunas (e.g., enterolactone) (Roy et al, 1997);
most appear benficial. Synthetic xenoestrogens include products of agriculture (e. g., some DDT
metabolites), chemical industries (e.g., alkylphenols), food and drug industries (e.g., bisphenol
A) (Roy et al., 1997); most appear detrimental. One possible explanation of the beneficial versus
detrimental effects of natural versus synthetic estrogens has been suggested to be their different
metabolism (Davis et al., 1997). For example, natural estrogens could be more easily
metabolized than synthetic estrogens and the natural estrogens may be more extensively
metabolized to 2-hydroxy estrogens that have primarily antiestrogenic/antiproliferative activity.
On the other hand, synthetic estrogens may metabolize less extensively and /or may metabolize
more extensively to 4-hydroxyestrogens that have primarily estrogenic/proliferative activity in
some ER+ cells. Detrimental effects can occur in response to environmental xenoestrogen
exposure in various non-mammalian species such as fish (White et al., 1994), reptiles (Guillette
et al., 1994), and birds (Fry et al., 1987). Some unwanted effects include decreased reproductive
capacities and feminization of males. P-nonylphenol, a biodegradation product of nonionic,
ethoxylated detergent surfactants used in industrial applications, reaches levels of the order of
mg/l in sewage effluents and of the order of  ng/l in drinking water. Levels of this order of
magnitude of p-nonylphenol and other alkylphenols detected in fish collected from polluted
waters are weakly estrogenic (Soto et al., 1991). Polychlorinated biphenyls (PCB) disrupt
26
endocrine function in various mammalian species (Birnbaum, 1994; Colborn et al., 1993;
Bergeron et al., 1994; McLachlan et al., 1993). These include whales (Martineau et al., 1988) and
seals (Reijnders, 1986).
       Exposure of laboratory animals to xenoestrogens such as bisphenol A can induce gender
related disorders (IARC, 1979). Bisphenol A, which leaches out from food packaging and plastic
materials (Knaak and Sullivan, 1966; Krishnan et al., 1993; Brotons et al., 1905; Bond et al.,
1980; Atkinson and Roy, 1995), produces adverse reproductive effects in rats and mice (Knaak et
al., 1966; Bond et al., 1980; Atkinson and Roy, 1995). A possible association of bisphenol A
with cancer of the hematopoietic systems of rats and mice is also likely (Ashby and Tennant,
1988). Other natural and synthetic xenoestrogens can cause different types of cancer, depending
on the nature, strain, and species of the tested animal (IARC, 1979). Noble rats exposed to
estrone develop breast cancer (Cutts, 1964). Other rats and mice exposed to diethylstilbestrol,
estradiol, or estrone develop breast, bladder, ovarian, testicular, lymphatic, uterine, or prostatic
tumors. Hamsters develop kidney and uterine tumors; rabbits develop endometrial tumors; and
dogs develop ovarian and breast tumors (IARC, 1979). Currently, many of the effects of
substituted p-phenols on non-aquatic animal species and humans are still unknown.
       Although still controversial, recent laboratory and epidemiological studies lead to a growing
concern that human cancer etiology may involve synthetic xenoestrogen exposure (Malone,
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1993). For example, exposure to dichlorodiphenyldichloroethane (DDE) or diethylstilbestrol
(DES) may lead to breast cancer development (Safe, 1995; Malone, 1993). Daughters of women
who took diethylstilbestrol during pregnancy had increased fertility problems (Herbst et al.,
1992) and some developed breast cancer or a rare form of vaginal cancer (Marselos and Tomatis,
1992). Moreover, malformations appeared in both male and female offspring from females
exposed to DES during pregnancy (Stillman, 1982). Other reproductive problems include sterility
in male factory workers exposed to kepone (Guzelian, 1982), and higher risk of spontaneous
abortion in female pharmaceutical workers exposed to estrogens (Taskinen et al., 1986).
          From a mechanistic standpoint, xenoestrogens can mimic the action of estrogen very
closely while many others may not mimic the mechanism of action of estrogen closely but may
only mimic some of estrogen effects. For instance, diethylstilbestrol binds to ERs via the direct
ligand-independent pathway and induces ER+ breast cancer cell proliferation. On the other hand,
other compounds such as o, p’-DDT do not bind directly to estrogen receptors but stimulate ER+
breast cancer cell proliferation by acting on ERs indirectly, via ligand-independent pathways
(Roy et al., 1997, Enan and Matsumura, 1998).
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4.2 Estrogenic Drugs and Acetaminophen
       Some pharmaceuticals such as estradiol and diethylstilbestrol (estrogenic prototypes),
quinestrol, chlorotrianisene, ethynylestradiol, equilenin, and mestranol (Roy et al, 1997) are
estrogenic drugs. However, there are examples of drugs, such as cimetidine and digitalis, that,
although not originally designed for estrogenicity, display this potential (Roy et al, 1997).
Acetaminophen was first chosen for this study because it is one of the drugs not originally
designed for estrogenicity but with potential for estrogenicity. Generally, xenoestrogens have
diverse chemical structures and structure-activity correlations are difficult to establish (Raloff,
1993). However, a minimal chemical structure resemblance with estrogen appears to be
sufficient for estrogenicity (Cunningham et al., 1997). The moiety that confers estrogenic activity
to many xenoestrogens is the p-phenol moiety (Soto et al., 1991, Cunningham et al., 1997).
Acetaminophen is a p-substituted phenol. Thus, because acetaminophen contains the p-phenol
moiety, it may show some effects that are similar to those shown by estradiol in estradiol target
cells (Cunningham et al., 1997). Furthermore, the choice of acetaminophen has other
justifications besides a structure-activity correlation. Acetaminophen is a common analgesic and
antipyretic. If shown to be estrogenic, it could impact certain individuals. A description of
acetaminophen and some studies relevant to this project is included below.
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4.3 Acetaminophen
4.3.1 Physicochemical Properties
       Acetaminophen has a multitude of names and is available in more than 800 combinations
(Prescott, 1996). Its formula is C8H9NO2 and molecular weight 151.16. It is a white odorless
crystalline powder with melting-point of 169-170.5	C. It is soluble in water (1:70, 1:20 at
100	C), ethanol (1:7), acetone (1: 13), chloroform (1:50), glycerol (1:40), methanol (1: 10),
propylene glycol (1:9) and solutions of alkali hydroxides. A saturated aqueous solution has a pH
~ 6. Dry, pure acetaminophen is stable to 45oC. Humid conditions that cause hydrolysis to p-
aminophenol, result in degradation and discoloration. It is slightly light sensitive in solution. It
has a pKa = 9.0-9.5, a partition coefficient, Pc = 6.237 (octanol: pH 7.2 buffer) and a protein
binding fraction Fb=0.25 (Prescott, 1996).
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4.3.2 Dosage and Use
Acetaminophen is available as 325-mg or 500-mg tablets. It is also available as 500-mg
gelatin capsules and as a mint-flavored liquid containing 500 mg/15 ml solution. For children,
drops (80 mg/0.8 ml), chewable tablets (80 mg), elixir (160 mg/5 ml) and coated capsules (160
mg/capsule) are available (Prescott, 1996).
       Acetaminophen is widely used as an analgesic and antipyretic drug. It is the preferred
alternative analgesic-antipyretic to aspirin, particularly for patients with coagulation disorders,
individuals with a history of peptic ulcer or who cannot tolerate aspirin, as well as for children.
The conventional oral dose for adults is 500-1000 mg. Dosing may be repeated every 4 h as
necessary, but the total daily dose should not exceed 4 g.  For children, the recommended dose is
l0-15 mg/kg; no more than five doses should be administered over 24 h. Prolonged use (for more
than ten days) is not recommended. The usual dose for rectal administration is equal to that for
oral administration (Prescott, 1996).
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4.3.3 Acetaminophen Studies. Estrogenic/Antiestrogenic Activity
       Acetaminophen has been studied in detail but most data relate to its hepatotoxic effects.
However, limited studies are reported on the interaction of acetaminophen with cells modulated
by estrogen. Generally, literature indicates that acetaminophen has mostly an inhibitory effect on
various cell types including those modulated by estrogen. However, it is important to mention
that most of the studies that show inhibitory effects of acetaminophen in various systems use
concentrations of acetaminophen that are well above concentrations considered toxic in humans
(Prescott, 1996). When female rats were given 250 mg/kg acetylaminofluorene without or with
acetaminophen at 11 g/kg for 20 weeks, mammary tumors were seen in 14/20
acetylaminofluorene-treated animals and in 7/20 in acetaminophen plus acetylaminofluorene
treatments. This indicates an antiestrogenic effect of acetaminophen on mammary tumors of
these rats at the concentrations used (Weisburger et al., 1973). However, it is important to point
out that acetaminophen metabolism in rats is completely opposite to acetaminophen metabolism
in adult humans (Prescott, 1996). There is an additional study examining acetaminophen
interactions with breast cells. Teicher et al. (1993) examined acetaminophen effects on murine
EMT-6 mammary carcinoma cells in culture to determine if this drug modulated the effects of
antitumor alkylators, and acetaminophen had no significant effect on alkylators.Another study
showed that when acetaminophen was administered to rats in sub-therapeutic doses, it was found
to inhibit intestinal carcinogenesis induced by dimethyl aminobiphenyl (Williams and
Iatropoulos, 1997).
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Recent studies reported that daily acetaminophen use in humans decreased risk of ovarian
cancer and decreased plasma estradiol levels (Cramer et al., 1998 a, b). In mice breeding studies,
Reel et al. (1992) and Boyd et al. (1970) found that 1.43 g/kg/day acetaminophen reduced the
number of litters per breeding pair, increased the percent abnormal sperm, and increased
testicular atrophy. In other studies, acetaminophen concentrations (corresponding to toxic plasma
levels achieved in humans) reduced progesterone production in cultured porcine granulosa cells
(Haney et al., 1987). Acetaminophen inhibited estrogen-induced vitellogenin production in
isolated trout liver cells at both acetaminophen levels that correspond to therapeutic and toxic
plasma levels in humans (Miller et al., 1999). Acetaminophen 5-50 
g/kg did not compete with
estradiol for binding to mice uterine estrogen receptors, and it did not increase uterine weight, an
estrogenic effect (Isenhower et al., 1986).
Acetaminophen was identified as a peroxisome proliferator in a 48-hour assay. In this assay,
acetaminophen upregulated chloramphenicol acetyl transferase fusion construct to rat acetyl CoA
oxidase stably transfected in a rat liver cell line (Lee et al. 1997). This induction suggested that
acetaminophen played a role in cell proliferation and tumor progression. Acetaminophen (0.1-0.3
mM) was also shown to enhance proliferation of lung carcinoma cells; it was suggested this
effect occurred via alterations of membrane lipids (Schonberg and Skorpen, 1997). It is important
to note that the latter two studies used relevant, pharmacological concentrations of
acetaminophen. Overall, all of the studies mentioned in this section suggest acetaminophen
displays a range of effects and it may act as an antiestrogen or an estrogen in some estrogen-
responsive systems while it may have no effects in others. These effects depend on cell type,
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concentrations of acetaminophen used, and assay conditions. Moreover, some of the inhibitory
effects of acetaminophen may be due to toxic effects. Prior to this project, there had been no
reports of effects of acetaminophen on proliferation of ER+ or ER- cultured breast cancer cells.
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5. EXPERIMENTAL MODELS
FOR STUDYING THE NORMAL AND CANCEROUS BREAST
5.1 In Vitro Models
5.1.1 Breast Cell Cultures Advantages and Disadvantages
       There are advantages offered by human cell culture, in vitro models relative to in vivo animal
models (Adams, 1988). First, to understand normal and aberrant epithelial cell growth control in
humans it is best to study human epithelial cells. While non-human and non-epithelial cell
studies provide valuable information, there are many differences between these cell types and it
is more likely that cells from humans provide more accurate models for human disease than
nonhuman cells. Second, cells can be grown in monolayer and are always available for
experiments at minimal cost. The unlimited growth of these cells allows one to perform
numerous experiments with homogenous cell populations. Third, all cells are exposed to the
same hormonal and nutritional conditions. Medium can be defined providing additional means
for controlling the environment and eliminating unknown serum factors. Due to these
advantages, cultured human breast cells offer good models especially for mechanistic studies of
pharmacologic agent action and for studies of proliferation and other critical phenomena that
govern breast cancer. A better understanding of these systems can lead to information that can be
exploited to develop better strategies to pharmacologically control this disease.
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       Such in vitro cell culture systems, however, have limitations. First, normal and aberrant
cellular processes in vivo involve complex interactions within three dimensional organ systems.
Thus, while cultured cells provide good models for homotypical cell interactions, they do not
provide heterotypical cell interaction information (unless cocultures are used). Second,
undetected viral or mycoplasmic contamination can alter growth rates and normal responses.
Overall, many hypotheses are difficult to test under in vivo conditions because it is impossible to
control all the variables involved. Eventually, hypotheses generated from in vitro experiments
require verification in the intact organism and vice versa, detailed studies of mechanisms of
action of various compounds requires in vitro controlled conditions.
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5.1.2 Normal Breast Cells in Culture
       Widely used in vitro models for studying the dynamics governing normal mammary cells are
the human mammary epithelial cells (HMEC). HMEC are derived from reduction mammoplasty
tissues followed by post-selection from subpopulations of normal cells that display long-term
growth. Post-selection cells grow rapidly (doubling times of 18-24 hrs). However, it is
noteworthy that cells with long-term growth potential represent only a unique subpopulation of
originally cultured cells. Only a small fraction (~3-10%) of normal epithelial cells in vivo show
detectable estrogen receptor levels and this population is preferentially localized in non-basal
layers. However, HMEC do not have estrogen and progesterone receptors (Stampfer and Bartley,
1987). Since medium that is fed to these cells includes insulin, glucocorticoid, EGF,
isoproterenol or other cAMP stimulator, bovine pituitary extract and transferrin, it is possible that
one or more of these factors negatively regulate ER/PR receptors and eventually an ER-/PR-
subpopulation adapts to culture conditions. Estrogen–induced epithelial proliferation does not
occur in response to estrogen unless cells are cocultured with stromal cells (Stampfer and
Bartley, 1987). It is believed that an interaction between various growth factors and estrogen are
responsible for normal mammary epithelial growth and while evidence from ER in epithelium
exists, it is not yet clear that growth responses of normal cells result from direct effects of
estradiol (Stampfer and Bartley, 1987).
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5.1.3 Breast Cancer Cells in Culture
       There are various breast cancer cell lines that can be used in cell culture research.
Among other characteristics, the retention of ER’s and PR’s by some breast cancer cells
is one feature of which this research is taking advantage. Cells used in this research
include MCF7, T47D, and ZR-75-1 cells that are ER+/PR+ and MDA-MB-231 and
HS578T cells that are ER-/PR- (Shymala, 1985; Clarke 1995). All these cell lines were
derived from pleural effusions from postmenopausal women with breast carcinomas and
they all have epithelial-like morphology. Levels of ER’s found in ER+/PR+ cells are
similar to those found in breast cancer biopsies. For example, MCF7 cells contain 60-100
fmoles of cytosol ER/mg cytosol protein (Kd=0.06-2.5nM), ZR-75-1, 30 fmoles/mg
(similar Kd) while freshly excised breast biopsies contain up to a few hundreds fmoles
ER/mg cytosol protein. Usually breast cancer cells that are ER+/PR+ express both wild
type and mutated receptors (Castles et al., 1995). MCF-7 cells have lower levels of ER
relative to ERZR-75-1 cells have only ER; and T47D cells have approximately equal
amounts of both alpha and beta (Register and Adams, 1998; Enmark et al., 1997).
Receptor occupancy by agonists leads to initial downregulation of ER’s and proliferation.
The ER+/PR+ cells are stimulated maximally by 10-8 - 10-9 M 17 -estradiol and
inhibited by > 10-7 M 17 -estradiol (Kasid et al., 1985). Proliferative endpoints often
monitored include 3H-thymidine incorporation, % cells in DNA synthesis phase of cell
cycle and cell numbers (Kasid et al., 1985). On the other hand, estrogen-independent cells
(e.g., MDA-MB-231) do not contain ER alpha's and do not exhibit estrogen-stimulation.
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However, these cells do contain some wild type and variant ER beta’s (Vlasic et al.,
1998).
       The T47D human breast cancer cell line has sublines that are ER positive and estrogen
responsive, ER positive and estrogen resistant, or ER negative (Horwitz 1990). T47D variants
used in this study include T47D co, T47DYA, and YB breast cancer cells. The breast cancer cell
line T47Dco (Leslie et al., 1992) is composed of multiple cell populations with low levels of
both wild type and mutant estrogen receptor (Leslie et al., 1992). T47Dco cells have 90% lower
ER levels than MCF7 cells (Berkenstam et al., 1989; Castles et al., 1995) and high PR levels
(Horwitz et al., 1986). The PR’s are independent of estrogen induction, and the T47Dco cell line
is estrogen- and antiestrogen-resistant (Horwitz and Friedenberg, 1985; Graham et al., 1990;
Leslie et al., 1992).Two of the three mutant T47Dco ER’s are truncated near the end of the DNA
binding domain and exhibit low DNA binding and constitutive function; a third mutant has a
large deletion spanning the hinge region and part of the hormone-binding domain (Leslie et al.,
1992; Horwitz 1990). If expressed, these mutant ER's lack hormone-binding capacity (Horwitz
1990). Other groups found that T47Dco expressed ER variant transcripts with exons 5 and 7
deleted (Castles et al., 1995).
       Sartorius et al, in 1994 developed other T47D variants to allow the study of each PR isoform
independently. A stable PR- subline (T47D-Y) of PR+ T47D breast cancer cells was first
selected then T47D-Y cells were stably transfected with expression vectors encoding PRA or
PRB. Two cell sublines were selected that express either B-receptors (T47D-YB) or A-receptors
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(T47D-YA) at levels equal to those seen in natural T47D cells. The receptors are properly
phosphorylated, and like endogenous receptors, they undergo ligand-dependent down-regulation.
Only B:B or A:A homodimers are present in each cell line (A:B heterodimers are absent). With
agonists, cAMP-dependent, transcriptional synergism of progesterone response element-
regulated promoters is seen in these cells. By contrast, in the presence of the antiprogestins
RU486 or ZK112993, inappropriate transactivation occurs in YB cells but not in YA cells
antiprogestins like ZK98299, that block PR-DNA binding, do not activate transcription in these
cells. In conclusion, all these breast cancer cell types are valuable models for studying effects
related to ER's or PR's.
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5.2 In Vivo Experimental Models
Nude Mice
        In order to better understand and characterize the proliferative effect of acetaminophen on
breast cancer cells and to determine the relevance of the in vitro findings, in vivo studies must be
carried out. Therefore, one of the goals of this research was to determine if the observed in vitro
effect of acetaminophen occurs also in vivo, in nude mice. The availability of the nude athymic
mouse provides one of the best systems for the study of tumors outside the body of the patient.
This mouse, homozygous for the nu mutation, is the most widely used immunodeficient rodent
model in cancer research. The nude mutation (nu) is located on mouse chromosome 11 and
homozygous mice are essentially athymic (Clarke, 1996). The lack of a fully functional thymus is
mainly responsible for the low levels of T-lymphocytes. Additionally, the virgin  B-cells are
present but B-cell maturation is defective. Despite the severe immunodeficiencies, the
homozygous nu/nu mice are remarkably robust because of their remaining immunocompetence.
A peculiarity of these mice is their increased levels of natural killer cells that exceed the levels
present in the normal mouse of the same background (Clarke, 1996).
       The ovariectomized mouse model used in our experiment is important because it provides an
endocrinologic environment equivalent with that of postmenopausal women (Clarke, 1996).
Estrogen supplementation is usually necessary for tumors to develop in these mice (Clarke,
1996). The main advantage for using this model is that, unlike in normal animals in which the
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immune system is intact and which usually rejects tumor implants, human breast tumors and cells
lines derived from human tumors can produce neoplasms when injected into nude mice
(Giovanella, 1974; Clarke 1996). These animals are necessary to logically extend in vitro
findings to an in vivo level but using the same cell types as those used in vitro.
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6. RESEARCH  PROJECT OBJECTIVES
       There are two main types of research objectives and experiments that this dissertation
addresses: in vitro and in vivo.  They are listed below:
I. In Vitro Studies
1) Determine if acetaminophen induces proliferation of breast cells. Test:
        a) Breast cancer cells (ER+/PR+; ER-/PR+; ER-/PR-; where ER refers to ERalpha)
        b) Normal breast cells
2) Determine if ERs in ER+/PR+ cells play a role in acetaminophen-induced  proliferation. Test
if:
       a) antiestrogens inhibit acetaminophen-induced proliferation,
       b) acetaminophen binds to ERs in breast cancer cells.
3) Determine if the p-phenol moiety in acetaminophen plays a role in proliferation.
4) Determine if acetaminophen metabolism can be detected in breast cancer cell microsomes.
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II. In Vivo Studies
       Determine if acetaminophen affects tumor growth in nude mice inoculated with ER+/PR+
breast cancer cells.
       The next section comprises a description of the methods used to accomplish this research
project. Then the following section summarizes the results from the experiments conducted to
accomplish the above objectives and the last section discusses the findings. The discussion
section also includes some suggestions regarding possible implications for humans and some
future experiments that may be done to continue this project.
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CHAPTER II. MATERIALS AND METHODS
1. Materials
The T47D, ZR-75-1, and HS578T cells were purchased from the American Type Tissue
Collection. Dr. J. Strobl (Department of Pharmacology and Toxicology, West Virginia
University) donated the MCF7 and MDA-MB-231 cells. Dr. Kathryn Horwitz (Department of
Endocrinology, University of Colorado) donated T47D variant cells. Corning tissue culture flasks
and dishes (35x10mm), Whatman GF/A microfiber filters, and disposable sterile pipettes were
purchased from Fisher, Pittsburgh, PA. Dulbecco’s Modified Eagle’s Medium (DMEM) and
Minimum Essential Medium Eagle (MEME) with or without phenol red (PRF), Fetal Bovine
Serum (FBS) regular or heat inactivated, glutamine, geneticin, and gentamicin were purchased
from BioWhittaker, Walkersville, MD. HMEC cell media (Mammary Epithelial Cell Growth
Medium, MEGM) and additives were from Clonetics (San Diego, CA). P-, m-, o-
acetamidophenol, trypsin, propidium iodide, and other chemicals were purchased from Sigma
Chemical Co., St. Louis, MO and were the highest quality available. [2, 4, 6, 7-3H] Estradiol
(88.0 Ci/mmol) and [methyl-3H] thymidine (80.0 Ci/mmol) were purchased from Amersham Life
Sciences. Seven-week-old ovariectomized and non-ovariectomized female BALB/c nu/nu mice
were purchased from Harlan Sprague Dawley, Madison, WI. Estrogen pellets were purchased
from Innovative Research of America, Toledo, OH. Rat S9 and human microsomes were
purchased from Gentest Corporation (Woburn, MA).
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2. Methods
2.1 Cell Culture
 The ER+/PR+ breast cancer cells, MCF7, T47D, ZR-75-1, and ER-/PR- cells, MDA-MB-
231, and HS578T cells were cultured in DMEM supplemented with 10 % FBS and 50 g /ml
gentamicin. The ER-/PR+ cells (T47Dco, T47DYA, T47DYB) were maintained in Minimum
Essential Medium Eagle (MEME) supplemented with 5 % heat inactivated FBS, 0.292 g/L
gentamicin, 6 ng/L insulin, and 10 ml/L of 100 x non-essential amino acids. T47DYA and
T47DYB cell culture medium was added geneticin. HMEC cells were maintained in MEGM
supplemented with bovine pituitary extract (13 mg/ml, 2ml), hydrocortisone (0.5 mg/ml, 0.5 ml),
epidermal growth factor (10 g/ml. 0.5 ml), and insulin (5 mg/ml, 0.5 ml).
Prior to experiments, all breast cancer cells were placed for 2-4 days in Phenol Red Free
(PRF)-DMEM supplemented with 2 % estrogen-free FBS and gentamicin. The medium must be
phenol red free because phenol red itself has estrogenic activity, namely it stimulates proliferation
and acts on the ER (Berthois et al, 1986; Rajendran et al., 1987). Because we studied the estrogenic
activity of acetaminophen, we wanted to avoid this confounding variable (phenol red in medium).
T47Dco cells were placed in PRF-MEME supplemented with 2 % estrogen-free heat inactivated
FBS, insulin, and amino acids. T47DYA and YB were added geneticin. HMEC cells were placed in
PRF-MEGM with the same additives as those for cell maintenance. HMEC receive bovine pituitary
extract instead of FBS; the bovine pituitary extract was tested and found to contain negligible levels
of estradiol (<2 pg/ml). The FBS was stripped of estrogen according to the charcoal-dextran
procedure described by Dabre et al. (1983). Analysis of stripped serum revealed negligible levels
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(<2 pg/ml FBS) of estradiol (Ongphiphadhanakul et al., 1998). As mentioned in the introduction,
these levels reflect prepubertal plasma estradiol levels that are ~ 5 pg/ml; these levels are not high
enough to induce breast development.
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2.2 Experimental Design
Initially, to investigate the effects of acetaminophen on breast cancer cell DNA synthesis,
a modified E-screen assay was designed to contain built-in redundancy. Two dichotomous groups
of breast cancer cells (ER+ and ER-) were included to assure consistency in terms of dichotomy
of response (e. g., ER+ cells were expected to respond to xenoestrogens while ER- cells were
not). Multiple cell lines within each group of ER+ and ER- cells assured consistency of response
within each group (e.g., T47D, MCF7, and ZR-75-1 cells were expected to show similar
responses). Initially, to determine what effects acetaminophen has on breast cancer cells, two
different endpoints that reflect DNA synthesis, 3H-thymidine incorporation into DNA and %
cells in the S phase of the cell cycle, assured consistency with respect to DNA synthesis patterns.
Later other endpoints were monitored such as cell number and ER binding. These are all
described in detail below. All cultures were depleted of estrogens as described above, then
medium was replaced daily. Medium contained no additions (negative control), 3nM 17 beta-
estradiol (positive control), or 0.03-1 mM acetaminophen. The same negative and positive
controls were used for all experiments.
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2.3 Endpoints in Vitro
3H-Thymidine Incorporation
 
3H-thymidine incorporation into newly synthesized DNA was measured as one means of
assessing the proliferative effects of estradiol and acetaminophen on breast cancer cells. In each
experiment, cultures were divided into treatment groups that included: (1) negative control
(medium alone); (2) positive control (3 nM estradiol); (3) 3 nM estradiol + 0.1 mM
acetaminophen; (4-7) 0.03 mM, 0.1 mM, 0.3 mM, and 1 mM acetaminophen, respectively.
The acetaminophen concentrations reflect therapeutic (0.03-0.1 mM) and toxic (1 mM)
plasma level counterparts in humans (Forrest et al., 1982; Jensen et al., 1996). The estradiol
concentration corresponds to physiological plasma levels in pregnant women (Vohrerr, 1967;
Berne and Levy, 1993). Two milliliters of cell suspension were plated into 35 mm culture dishes
or 6-well plates. Plating densities (cells/ml) varied from 0.3x105 (estrogen-nonresponsive cells)
to 1.5x105 (estrogen-responsive cells), because estrogen-nonresponsive cells proliferate faster
than estrogen-responsive cells.
Cells received phenol red-free and estradiol-free medium for a few days. Then, for most
experiments, each day medium was aspirated and fresh media without or with compounds (as
indicated in figure legends in the results section) were added once daily for the next three
consecutive days. The exception to this dosing regimen was one set of experiments that was done
to determine if the effects of acetaminophen are still observed under a different dosing regimen.
In this case, cells received medium without or with compounds once, then after 1 day, cells
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received a second treatment or cells received the first treatment; after 3 days cells received a
second treatment and were analyzed. Together with administration of the last treatment, cells
received 3.6 Ci/ml 3H-thymidine (17 Ci) for 4 hours. Cells were washed with Hanks’
Balanced Salt Solution, and then 10 % trichloroacetic acid (TCA) was added to precipitate DNA.
TCA was removed and the precipitate was dissolved in 1ml 0.1 N NaOH, then reprecipitated
with 1 ml 20 % TCA and subsequently filtered on to GF/A filters. The filters were rinsed with
0.1 N HCl, then 70 % ethanol and dried. The 3H-DNA was quantitated in a scintillation counter
(Beckman Instruments, LS500TOL model). Each treatment group was assayed in triplicate and
each experiment was repeated at least three times. Results from single, representative
experiments are presented as counts per minute (cpm) 3H-thymidine incorporated into DNA and
reflect relative DNA synthesis rate of the seven treatment groups within each cell line.
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Percent S Phase Cells
Flow cytometry was used to independently confirm the results obtained from 3H-
thymidine incorporation experiments for 3 of the cell lines (ER+: MCF7, T47D; ER-: MDA-MB-
231) and for T47 D variants. In flow cytometry studies, cultures were set up as described above,
except that the cells were plated into 75 cm2 flasks. Cells were initially placed in phenol red- and
estradiol-free medium. Then each of the following three days, old medium was aspirated and
fresh medium with or without compounds was added once daily. For these experiments, only
0.1mM that reflects therapeutic plasma levels in humans and 1 mM acetaminophen that reflects
toxic levels in humans were selected for further testing. At the end of these experiments, cells
were collected for flow cytometry analysis while medium was collected for LDH analysis. Cells
were washed with Hanks’ Balanced Salt Solution, collected by trypsinization and suspended in 1
ml Solution A (2 g trisodium citrate, 2 ml NP-40, 1.044 g spermine tetrahydrochloride, 0.121g
Tris dissolved in 2 l distilled water) containing 0.03 mg trypsin/ml for 10 minutes. Then, 0.75 ml
Solution A containing trypsin inhibitor (0.03 mg/ml) and RNase (0.08 g/ml) was added for 10
minutes, followed by 0.75 ml solution A containing propidium iodide (0.4 mg/ml) and spermine
(1.16 mg/ml) for an additional 10 minutes. Samples were analyzed in the WVU Flow Cytometry
Facility with a Fluorescence Activated Cell Analyzer (Becton Dickinson Immunocytometry
Systems, San Jose, CA). Results represent the % cells in the S phase of the cell cycle, determined
using the Modfit LT 2.0 software (Verity Software House).
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Cell Numbers
Because DNA synthesis can proceed toward either apoptosis or proliferation (Wiger et al.,
1997), cell numbers have been determined to establish if acetaminophen induces proliferation.
Estrogen-depleted cells were exposed to acetaminophen and estradiol for longer time periods to
assess effects on cell number (see figure legends). Cells were plated at densities indicated in figures,
compounds were added and at indicated times cells were trypsinized and counted in a
hemocytometer. Results are presented as numbers of viable (trypan blue excluded) cells/plate, and
viability was 95%.
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Cytotoxicity
The objective of these studies was to determine if acetaminophen has toxic effects on
breast cancer cells. The culture medium from cells was tested for LDH release to assess general
cytotoxicity using a Sigma Diagnostics kit (Cabaud and Wroblewski, 1958; Amdador et al.,
1963), and samples were read on a Gilford Response II Spectrophotometer.
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Whole Cell ER Binding Assays
The objective of these studies was to determine if acetaminophen competes with estradiol
for binding to ERs. These assays were conducted as described with minor modifications (Strobl
et al., 1984). Briefly, MCF7 cells were placed in 6-well plates in estrogen-depleted medium, then
media with 3H-estradiol (0.1-5nM) without or with 600 nM excess unlabeled estradiol were
added. Experiments were stopped after 45 minutes or 18 hours incubation periods. Two time
periods were investigated because some compounds with low affinity for the estrogen receptors
can bind to receptors but after longer incubations that allow to reach steady-state conditions
(Nagel et al., 1998).
Cells were rapidly rinsed twice with 2 ml PBS, then lysed with 500 l 0.2 N NaOH,
neutralized with 250 l 2 N HCl for 15 minutes at room temperature, and counted in 4 ml Ecolite
scintillation fluid. Kd was determined to be ~0.1nM then subsequent experiments determined the
ability of 0.1-10 nM unlabeled estradiol and of 0.1M-1mM acetaminophen to compete with
0.1nM 3H-estradiol for binding to ER’s. Total and nonspecific binding were determined
experimentally, then nmoles of specific binding of labeled estradiol were calculated.
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Metabolism Studies
Cell Growth, Treatment and Microsomal Preparation
The objective of these studies was to determine if acetaminophen metabolism could be
detected in microsomes from breast cancer cells. Two types of cells were used for these
experiments: ER+/PR+ cells (MCF7) and ER-/PR- cells (MDA-MB-231). Cells were grown such
that 50-60 T75 cm2 flasks of ~70 % confluent cells would be available for each of the four
treatments involved and for the subsequent preparation of microsomes. Cells were depleted of
estradiol and phenol red for a day then the controls received medium; the TCDD group received
10 nM TCDD; the beta-naphtoflavone (BNF) group received 40 M beta-naphtoflavone; and the
acetaminophen group received 0.1 mM acetaminophen for 1 day. The rationale for the treatment
with TCDD and BNF inducers was to induce the cytochrome P450 enzymes, which are capable
of metabolizing acetaminophen. The next day, microsomes were prepared according to the
procedure described in Lipscomb et al., 1998. Briefly, cells were isolated and sonicated in ice-
cold homogenization buffer then centrifuged at 9,000g for 20 minutes. The supernatant was
decanted and centrifuged again at 100,000g for 90 minutes. The resulting pellet was resuspended
in a microsome wash solution and was recentrifuged at 100,000g for 90 minutes. Then the
microsomes were resuspended in a small volume of resuspension solution containing 0.1 M
potassium phosphate buffer (pH ~7.2), 100 mM EDTA, and 20 % glycerol. The microsomes
were stored at -80C  for a few days up to a few weeks. The MCF7 experiment was done once
and the MDA-MB-231 experiment was done twice.
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Protein Level Measurement
Protein standards were prepared from bovine serum albumin in PBS from a 1 mg/ml
stock. The microsome samples were diluted to 100 l total volume PBS. Bradford reagent (1 ml)
was diluted 1:4 in water before use and 1 ml of mixture was added to each tube. After 20 minutes
A595 was determined using a spectrophotometer. The amount of protein was subsequently
calculated based on the standard curve.
HPLC Method for Detection of Metabolism
The procedure for detection of acetaminophen-cysteine metabolites by HPLC was as
described in Zaher et al., 1998. Assayed contained 125 l of microsomes (or S9 fraction)
incubated with 250 l of cofactor solution (20 mM glucose-6-phosphate, 15 mM MgCl2, .83 mM
NADP, 4 IU glucose-6-phosphate dehydrogenase) and 250 l of 15 mM cysteine. The N-
acetamidoquinone intermediate was trapped and transformed to the cysteine metabolite of
acetaminophen. Controls included non-induced human liver microsomes and rat liver S9 fraction
induced with Arochlor. The protein concentrations were measured as described above. Assays
were preincubated at 37oC for 10 minutes. Then, 250 l 15 mM acetaminophen were added to
initiate reactions to each incubation sample except for some controls that did not contain
acetaminophen.  Twenty minutes after adding acetaminophen, reactions were stopped by addition
of 750 l of ice-cold methanol. Additional controls were treated first with methanol then with the
rest of the mixture to determine if acetaminophen shows any nonspecific binding to other SH
groups. Other controls included solutions blanks and S9 + cofactor; S9 + cysteine; S9 +
acetaminophen; S9 + cysteine + cofactor, S9 + cofactor + acetaminophen, and S9 + cysteine +
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acetaminophen. After incubation, the samples were stored at -20oC overnight. The next day,
samples were centrifuged at 4oC and the supernatants were filtered using Millipore filters (0.22
m). NaOH was added to each HPLC sample to give a final pH~9. Samples (injection volume
100  l)  were analyzed by HPLC using a C18 column and UV detector at 254 nm. The mobile
phase was run at 1ml/min and contained 12.5% methanol, 1% acetic acid in deionized distilled
water at final pH 2.9 (Zaher et al., 1998). Retention times for acetaminophen and acetaminophen-
cysteine were 10.3 and 7.7 minutes, respectively.
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2.4. Endpoints in Vivo
Tumor Growth
The objective was to determine if acetaminophen stimulates proliferation of MCF7 cells in
vivo. The effects of acetaminophen on onset and/or progression of MCF7 tumors in nude,
ovariectomized mice were investigated. The rationale for ovariectomized mice was to mimic the
set up in vitro situation as closely as possible. The number of mice used was 40, with 10 mice per
treatment group, and the experiment was conducted for 44 days. The treatment groups were: 1)
negative control (no additions); 2) positive control, estradiol (E) pellets (60-day release); 3)
estradiol pellets 21-day release then acetaminophen (A) gavaged daily for the next 23 days (days
22-44); 4) acetaminophen gavage daily from day 1 to day 44. Mice were gavaged with 150 mg/kg
acetaminophen, a dose that does not induce hepatotoxicity in mice (Prescott, 1996).
Ovariectomized mice were acclimated for a week then randomized. The mice were kept in
sterile cages and bedding. Mice were fed Purina mouse chow 5058 (St. Louis, MO) and allowed
sterile water ad libitum. The temperature was maintained at 26-29oC and the animals were kept
under a 12-hour light and 12-hour dark cycle. Animals were kept inside a laminar-flow air
filtration system.
On Day 0, 1 day before cell inoculation, 1 estradiol pellet per mouse (60-day release 1.7 mg
estradiol/pellet) was implanted into each mouse within group 2 (positive control, E group). The
implants occurred on the back of the neck of each animal. In addition, 1 estradiol pellet was
implanted into each of the 10 mice (21-day release 0.5 mg estradiol/pellet) within treatment group 3
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(E + A) group. On Day 1, MCF7 cells were trypsinized, and inoculated at ~ 8x106
cells/0.1ml/mouse. Inoculation was performed in the fat pad of the upper left mammary gland using
a tuberculin syringe equipped with a #27 needle. Cell viability was 96% as determined by trypan
blue exclusion. Tumor growth was recorded twice a week using a caliper. The volume was
calculated using the formula Vtumor= 1.33rshort2rlong (Clarke, 1996).
2.5 Statistics
Data were analyzed using one and two way (time course studies) ANOVA and Student t-
tests. Data are expressed as endpoint means  standard error. If p<0.05, differences among means
were considered statistically significant. Sample sizes were as follows: 3H-thymidine
incorporation experiments, n = 3, binding assays, n = 3, LDH, n = 3, % S phase cells, n = 1 or 2
(see figure legends).
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CHAPTER III. RESULTS
3.1 Acetaminophen Effects on Breast Cells in Culture
Figure 3.1 shows that estradiol and selected xenoestrogens contain the phenol moiety that
is believed to participate in the estrogenic activity of these compounds. Note that acetaminophen
also contains the phenol moiety.
Figure 3.1 Chemical structures of selected xenoestrogens and of acetaminophen.
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3.1.1 3H-Thymidine Incorporation
The first set of studies was conducted to determine if acetaminophen mimics estradiol by
stimulating proliferation in selected breast cells. Three proliferation endpoints were evaluated:
(1) 3H-thymidine incorporation; % S phase cells and (3) cell numbers. Results from experiments
investigating 3H-thymidine incorporation are presented below.
Figures 3.2a, b, and c show the effects of acetaminophen on DNA synthesis in the
ER+/PR+ breast cancer cell lines MCF7, T47D, and ZR-75-1, respectively. As expected, relative
to control, 3nM estradiol increases 3H-dT incorporation into the DNA of these cells. All of the
ER+/PR+ cells also respond to acetaminophen. Relative to control, 0.03 mM acetaminophen
induced a small but significant increase in DNA synthesis (p<0.05) in T47D (Figure 3.2b) and
ZR-75-1 cells (Figure 3.2c) but this effect was not statistically significant (p>0.05) in MCF7
cells (Figure 3.2a).
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Figure 3.2 Effects of acetaminophen on 3H-thymidine incorporation into DNA in estradiol-
responsive (ER+/PR+) human breast cancer cells: (a) MCF7, (b) T47D, and (c) ZR-75-1.
Cells were placed in estrogen-free PRF-DMEM, then three consecutive doses (1 dose/day) of 3
nM estradiol (E), 0.03-1 mM acetaminophen (A), 3nM + 0.3 mM A (MCF7), or 3 nM E + 0.1
mM A (T47D; ZR-75-1) were administered (see experimental design). Incorporation of 3H-
thymidine (3H-dT) into DNA was determined 4 hours after the last addition and is reported as
mean 3H-dT incorporated into DNA (expressed in counts per minute, cpm; n=3) +/- standard
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error of the mean. Symbols * and # indicate statistically significant differences in means (p <
0.05) relative to control and estradiol treatments, respectively.
Figure 3.2 shows that 0.1 mM (T47D and ZR-75-1) and 0.3mM (MCF7) acetaminophen
induced maximal increases in 3H-dT incorporation (p<0.05) while 1 mM acetaminophen induced
a smaller increase in 3H-dT incorporation. For MCF7 and T47D cells, the relative DNA synthesis
induced by 1mM acetaminophen is small but significantly different from control (p<0.05), while
for ZR-75-1 this effect is not significantly different from control (p>0.05). The relative
magnitude of DNA synthesis induced by 0.1 mM acetaminophen (T47D and ZR-75-1) and 0.3
mM acetaminophen (MCF7) is approximately equal to that induced by 3 nM estradiol.
Acetaminophen reproducibly stimulated DNA synthesis in all the ER+ cells tested. However, in
different experiments, the relative magnitudes of acetaminophen- and estradiol-induced DNA
synthesis varied somewhat (Figures 3.2 a, b). In T47D and ZR-75-1 cells, the 3 nM estradiol +
0.1 mM acetaminophen mixture induced an increase in DNA synthesis comparable in magnitude
to that of 3 nM estradiol alone (p>0.05). In MCF7 cells, the mixture induced a DNA synthesis
rate that is slightly greater than either estradiol alone or acetaminophen alone.
Figures 3.3a and 3.3b show the effects of estradiol and acetaminophen on the estrogen-
nonresponsive breast cancer cells, MDA-MB-231 and HS578T, respectively. In these cells,
neither estradiol nor acetaminophen increased DNA synthesis (p>0.05). For MDA-MB-231cells
(Figure 3.3a), 1mM acetaminophen significantly reduced DNA synthesis.
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Figure 3.3 Effects of acetaminophen on DNA synthesis in estradiol-nonresponsive (ER- /
PR-) human breast cancer cells: (a) MDA-MB-231 and (b) HS578T. Treatments and data
collection occurred as described in Figure 2. Symbols * and # indicate statistically significant
differences in means, n=3 (p < 0.05) relative to control and estradiol treatments, respectively.
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When the normal human mammary epithelial cells, HMEC, were tested in a similar
manner with the breast cancer cells, neither acetaminophen nor estradiol induced any stimulatory
effects (except that estradiol appeared slightly inhibitory after 3 additions).
Figure 3.4 Effects of acetaminophen on DNA synthesis in normal breast, ER-/PR- HMEC
cells. Treatments and data collection occurred as described in Figure 2 except data were
collected after 2 (a) and after 3 (b) additions of treatments to cells (n=3).
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3.1.2 Percent S Phase Cells
Figures 3.5a, b, and c present the effects of acetaminophen and of estradiol on % MCF7,
T47D, and MDA-MB-231 cells in S phase, respectively. In these studies, flow cytometry was
used to determine % cells in the S phase of the cell cycle. In both MCF7 and T47D cells, 0.1 mM
acetaminophen alone and 3 nM estradiol alone induced an approximately 2 fold increase in the
% S phase cells relative to control cells (Figures 3.5a and 3.5b). The combination of
acetaminophen and estradiol also induced an approximately 2-fold increase in % S phase cells.
In all the ER+ cells tested, both the % S phase cells (Figures 3.5a and 3.5b) and the 3H-dT
incorporation into DNA (Figures 3.2a and 3.2c) were increased by acetaminophen and by
estradiol. Figure 4c shows that neither estradiol nor acetaminophen increased % S phase cells of
ER-, MDA-MB-231 cells (assessed by flow cytometry), also consistent with 3H-dT incorporation
data (Figure 3.3a).
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Figure 3.5 Effects of acetaminophen on % S phase cells in estradiol-responsive (ER+)
human breast cancer cells, (a) MCF7 and (b) T47D, and estradiol-nonresponsive (ER-)
breast cancer cells, (c) MDA-MB-231. Cells were plated in estrogen-free, PRF-DMEM, then
three consecutive doses (1 dose/day) of 3 nM estradiol (E), 0.1 mM, 1 mM acetaminophen (A), 3
nM E + 0.3 mM A (MCF7) or 3 nM E + 0.1 mM A (T47D; MDA-MB-231) were administered
(see experimental design). Cells were collected and analyzed 4 hours after the last addition.
Results are presented as % S phase cells. The sample size in the experiments shown was n=1,
experiments were repeated were found reproducible and representative results are shown.
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3.1.3 Cell Numbers
To verify that the indirect proliferative endpoints tested reflect increases in cell numbers,
ER+/PR+ breast cancer cells were counted after being cultured in the presence and absence of
acetaminophen and estradiol. Results are shown below for one of the cell lines tested (Figure
3.6) and they are consistent with previous data. Figure 3.6 shows the effects of acetaminophen
and estradiol on T47D cell proliferation as a function of time. Two days after first addition of
drugs (day 3), only 3nM estradiol + 0.1 mM acetaminophen induced a significant increase (~1.5
fold) in cell number above control. Subsequently, both estradiol and acetaminophen induced
statistically significant increases in cell proliferation above control. By day 9, 0.1 mM p-
acetamidophenol (acetaminophen), estradiol, and estradiol + acetaminophen induced 1.8, 3.1,
and 4.0 fold increases in cell proliferation above control, respectively. Physiologic
concentrations of estradiol are typical positive controls in tests evaluating estrogenicity of
chemicals, and the proliferation induced by estradiol in this study is consistent with previous
studies (Kasid et al., 1985).
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Figure 3.6 Effects of 0.1 mM acetaminophen on T47D cell proliferation. Cells were seeded
into 35x10 mm plates in estrogen-depleted medium for 2 days. Fresh estrogen-free medium was
then added at days 1, 3, and 6 with indicated compounds: 0.1 mM acetaminophen (A), 3nM
estradiol (E) or 0.1 mM acetaminophen + 3 nM estradiol (E+A); controls (C) contained vehicle
only. Cell numbers were determined by hemocytometer counts at days 3, 5 and 9; “*” indicates
statistically significant differences from control.
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3.1.4 Acetaminophen Induces 3H-Thymidine Incorporation under Other Dosing Regimens
Another objective of this study was to determine if acetaminophen stimulates
proliferation responses under different, simpler dosing regimens. Previously, we established that
0.1 mM acetaminophen induces 3H-dT incorporation into DNA if added to cells once daily for
three days. The results shown in Figure 3.7 below are from studies done by adding
acetaminophen to cells once for one day (a) and once for three days (b, c) to MCF7 cells (a, b)
and T47D cells (c). Acetaminophen does not stimulate 3H-dT incorporation into DNA of MCF7
cells after 1 day (a) although estradiol does induce 3H-dT incorporation in this period. However,
1 acetaminophen or estradiol treatment is sufficient to induce this response after 3 days (b, c) in
both MCF7 and T47D cells.
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Figure 3.7 Acetaminophen stimulates 3H-dT incorporation into DNA under a 1 dose/3days
dosing regimen in MCF7 cells (b) and T47D cells (c) but not under a 1 dose/1 day regimen
in MCF7 cells (a). Cells were depleted of phenol red and estradiol 2-4 days, then cells were fed
once fresh medium (C), or medium with 3nM estradiol (3nME) or 0.1 mM acetaminophen (0.1
mM A). Cells were exposed to 3H-dT in the last 4 hours of culture, then analyzed by scintillation
counting after 1 day (a) or 3 days (b, c), as described in the methods section.
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3.2 Cytotoxicity
Medium from cultures used for flow cytometry was assayed for LDH activity. None of
the treatments cause significant loss of cellular LDH into medium (data not shown). This
suggests that the effects induced by acetaminophen are not cytotoxic and the fact that 1 mM
acetaminophen does not induce proliferation in ER+ cells does not appear to be due to
cytotoxicity.
3.3 Mechanism of Acetaminophen-Induced Proliferation
3.3.1 T47D Variants Studies
Once it was established that acetaminophen stimulates proliferation of ER+/PR+ breast
cancer cells, we investigated how may acetaminophen induce this effect. It was apparent that
there is a correlation between acetaminophen effects and the presence or absence of ER/PR; that
is, like with estradiol, only cells that are ER+/PR+ undergo acetaminophen-induced proliferation.
In order to understand the involvement of ER’s in acetaminophen-induced proliferation, T47D
variants were tested. These variants, as explained in introduction and methods have low to
negligible ER but high PR levels. The rationale for testing these cells was to determine if
acetaminophen stimulates proliferation of these cells in order to differentiate between effects
mediated by ER and PR. Acetaminophen could elicit effects like estrogen due to its phenol
moiety. If acetaminophen acted like estradiol, these ER deficient cells were expected not to
proliferate. On the other hand, acetaminophen also contains an acetyl group, like some
progestins. Thus, if acetaminophen, acted like some synthetic progestins such as alpha-
ketogestrel, these cells were expected to proliferate and if it acted like progesterone, these cells
should be inhibited. Second, unlike the cells used in previous experiments, the three T47D
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variants (T47Dco, T47DYA and T47DYB) allow some level of discrimination between effects
mediated by ER and by PR. For example, T47Dco have low ER, high PR AB heterodimers, A
homodimers and B homodimers, while T47DYA have PRA homodimers only and T47DYB
have PRB homodimers only.
Results presented in Figure 3.8 show that acetaminophen does not induce proliferation in
either T47Dco or T47DYA or T47DYB cells (Figures 3.8a, b, c, d). On the contrary, at high
concentrations ~1 mM, like in MDA-MB-231 cells, acetaminophen inhibits proliferation. Such
data are consistent with previous data and further support the hypothesis that acetaminophen-
induced proliferation most likely depends on high ER levels but not PR (AB, A, B) and that
acetaminophen mimics some estradiol effects (e.g., proliferation or lack of proliferation in
specific cell types).
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Figure 3.8 Effects of acetaminophen on T47Dco (a, b), T47DYA (c), and T47DYB (d) cells.
(a, c, d) Cells were plated into T75 cm2 duplicate flasks in estrogen-depleted medium for 2-4 days,
then medium without additional compounds (control) or with compounds was replaced daily for 3
days. Cells were then analyzed by flow cytometry (see methods). Abbreviations: C = control
(medium only); E = 3nM estradiol; 0.03 – 1 mM A = 0.03 – 1 mM acetaminophen. (b) Cells were
plated in triplicate into 6 well plates as in  (a), and 3H-thymidine incorporation into DNA was
determined as previously described; abbreviations are the same as (a).
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3.3.2 Antiestrogen Studies
To obtain further information about the involvement of ER in acetaminophen-induced
proliferation, experiments were performed to determine if acetaminophen-induced proliferation
could be inhibited by two antiestrogens, a partial antiestrogen (4-hydroxytamoxifen) and a
complete antiestrogen (ICI182,780). The rationale was that if acetaminophen-induced
proliferation involves ER, as data so far indicate, then antiestrogens should inhibit this effect.
The following figures show effects of two antiestrogens on acetaminophen-induced proliferation
of MCF7 and T47D cells, as reflected in % cells in S phase of the cell cycle and cell number,
respectively. Effects of antiestrogens on acetaminophen-stimulated incorporation of 3H-
thymidine into DNA were also assessed and found consistent with these results (data not shown).
In MCF7 cells, ICI 182,780 inhibits acetaminophen- (Figure 3.9a) and estradiol-induced
increases in % S phase cells (Figure 3.9b).
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Figure 3.9 Effects of ICI 182,780 on (a) acetaminophen- and (b) estradiol-induced %
S phase MCF7 cells. Cells were plated in T75 cm2 flasks in estrogen-depleted medium for 2-4
days, then medium without additional compounds (control) or with compounds (treatments) was
replaced daily for 3 days; cells were then analyzed by flow cytometry (see experimental section).
Treatments in (a) are: (1) control; (2) 3 nM 17 -estradiol; (3) 10-7 M ICI 182,780; (4) 0.3 mM
acetaminophen; (5-10) 0.3 mM acetaminophen + ICI 182,780 at 10-11 M (5), 10-10 M (6), 10-9 M
(7), 10-8 M (8), 10-7 M (9), and 10-6 M (10), respectively. Treatments in (b) are: (1) control; (2)
3nM estradiol, (3) 10-7 M ICI 182,780, (4-5) 3nM estradiol + ICI 182,780 at 10-9 M (4) and 10-7
M (5), respectively. Results depict % S phase cells (n=2); “*” indicates statistically significant
differences relative to control; and “#” indicates statistically significant differences relative to
estradiol.
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Figure 3.10 below shows that 4’-hydroxytamoxifen also inhibits both acetaminophen-
and estradiol-induced increases in % MCF7 cells in S phase.
 Figure 3.10 Effects of 4’-hydroxytamoxifen on acetaminophen- and estradiol-
induced % S phase MCF7 cells. Cells were treated as in Figure 3.9. Treatments are: (1) control;
(2) 3 nM 17 -estradiol; (3) 10-6 M 4’-hydroxytamoxifen; (4) 0.3 mM acetaminophen; (5-7) 0.3
mM acetaminophen + 4’-hydroxytamoxifen at 10-8 M (5), 10-7 M (6), 10-6 M (7), respectively;
(8-9) 3nM estradiol + 4’-hydroxytamoxifen at 10-7 M (8), and 10-6 M (9), respectively. Results
depict % S phase cells; “*” indicates statistically significant differences relative to control; and
“#” indicates statistically significant differences relative to estradiol.
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Figure 3.11 shows that, as expected, neither acetaminophen, estradiol nor ICI 182,780
have any effect on % S phase cells in ER-/PR-, MDA-MB-231 cells.
Figure 3.11 Effects of ICI 182,780 on % S phase MDA-MB-231 cells. Cells were
treated as in Figure 3.9. Treatments are: (1) control; (2) 3 nM 17 -estradiol; (3) 10-7 M ICI
182,780; (4) 0.1 mM acetaminophen; (5) 3nM estradiol + 10-7 M ICI 182,780, and (6) 0.1 mM
acetaminophen + 10-8 M ICI 182,780 (6). Results depict % S phase cells.
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Figure 3.12a shows that ICI 182,780 inhibits both acetaminophen- and estradiol-induced
increases in MCF7 cell number, consistent with studies demonstrating that 10-7 M ICI 182,780
inhibits acetaminophen and estradiol stimulation of % S phase cells. In addition, these data are
consistent with other studies that demonstrate inhibition of estradiol-induced responses by ICI
182,780 at comparable concentrations (Noyes et al., 1996). Figure 3.12b shows that 4’-
hydroxytamoxifen (10-6 M) also inhibits acetaminophen- and estradiol-induced MCF7 cell
proliferation. Similar results were obtained with T47D cells (Figure 3.13)
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Figure 3.12 Effects of (a) ICI 182,780 and (b) 4’-hydroxytamoxifen on acetaminophen- and
estradiol-induced MCF7 cell proliferation. Cells were plated in 35x10mm dishes, depleted of
estradiol, and then medium with compounds were replaced twice over 7 days. Cell numbers were
determined in presence of trypan blue from hemocytometer counts (see experimental section).
Treatments in (a) are: () control; () 3 nM 17 -estradiol; () 10-7 M ICI 182,780; () 0.3
mM acetaminophen; () 0.3 mM acetaminophen + 10-8 M ICI 182,780; () 3nM estradiol + 10-7
M ICI 182,780. Treatments in (b) are: () control; () 3 nM 17 -estradiol; () 10-6 M 4’-
hydroxytamoxifen; () 0.3 mM acetaminophen; () 0.3 mM acetaminophen + 10-6 M 4’-
hydroxytamoxifen; () 3 nM estradiol + 10-6 M 4’-hydroxytamoxifen; “*” indicates statistically
significant differences relative to control.
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Figure 3.13 demonstrates that, as in MCF7 cells, addition of either ICI 182,780 (Figure
3.13a) or 4’-hydroxytamoxifen (Figure 3.13b) to T47D cells inhibits both acetaminophen- and
estradiol-induced proliferation.
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Figure 3.13 Effects of (a) ICI 182,780 and (b) 4’-hydroxytamoxifen on acetaminophen-
induced T47D cell proliferation. Cells were treated as in Figure 5; Treatments in (a) are: ()
control; () 3 nM 17 -estradiol; () 10-7 M ICI 182,780; () 0.1 mM acetaminophen; () 0.1
mM acetaminophen + 10-8 M ICI 182,780; (  ) 3nM estradiol + 10-7 M ICI 182,780. Treatments
in (b) are: () control; () 3 nM 17 -estradiol; () 10-6 M 4’-hydroxytamoxifen; () 0.1 mM
acetaminophen; () 3 nM estradiol + 10-6 M 4’-hydroxytamoxifen; () 0.1 mM acetaminophen +
10-6 M 4’-hydroxytamoxifen; “*” indicates statistically significant differences relative to control.
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3.3.3 ER Binding Assays
Evidence points to ERs involvement in acetaminophen-induced proliferation. The
obvious question then was whether acetaminophen mimics estradiol and binds to ER. Because
high specific activity radiolabeled acetaminophen is not available to determine direct binding to
ER, indirect experiments (competition) were done to answer this question. In addition, two
important factors have been reported to modulate weak xenoestrogen activity: time of incubation
and presence of serum in media (Nagel et al., 1998). Thus, experiments were done in whole cells
at 45 minutes and 18 hours and + or – serum (FBS) to maximize the conditions under which
even weak estrogens can be detected (Nagel et al., 1998).
Figure 3.14 shows that a 107-fold molar excess of acetaminophen did not compete with
estradiol for binding ERs in MCF7 cells after 18 hours. The removal of FBS and the increase in
incubation time to 18 hours are changes supposed to improve detection of even weak
xenoestrogens (Nagel et al., 1998). However, acetaminophen did not compete with estradiol for
binding ERs in MCF7 cells at 18 hours nor was there any significant increase in acetaminophen
binding to ER if the FBS was absent or present. Thus, it appears that acetaminophen does not
bind to ER at the same site at which estradiol binds in whole breast cancer cells.
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Figure 3.14 Acetaminophen does not compete with estradiol for binding estrogen receptors in
MCF7 cells. Cells were plated in 6 well plates and depleted of estrogen. Then media with 3H-
estradiol (0.1nM)  0.1-10 nM estradiol or  0.1M-1mM acetaminophen were added for 18 hours
to determine 3H-estradiol total binding. Additional plates were treated with 3H-estradiol (0.1nM) +
600 nM excess estradiol to determine nonspecific binding. Specific binding was determined by
subtracting nonspecific from total binding (see details in methods section). Representative results
are shown and depict % specific binding by 0.1nM 3H-estradiol in the presence of competing
estradiol (, ) or acetaminophen (, ) and +() or – () FBS.
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3.3.4 Acetaminophen Isomers Studies
The question addressed in these experiments is whether the position of the phenolic
substituent is a structural feature of acetaminophen that determines its activity as a proliferation
stimulator. As mentioned, such hypothesis is based on suggestions that the phenol moiety oriented
in the para position is important for chemicals to display estrogenicity (Cunningham et l997;
Anstead et al., 1997). Therefore, the positional isomers of acetaminophen, the p-, m- and o-
acetamidophenol were evaluated to determine if all, some, or only acetaminophen (p-
acetamidophenol) induces proliferation. In Figure 3.15a, the effects of the acetaminophen positional
isomers (0.1mM) on T47D cell proliferation are compared. At day 6, relative to control cell number,
p-acetamidophenol increased proliferation 1.6-fold, m-acetamidophenol increased proliferation 1.2-
fold, while o-acetamidophenol had no effect on cell number; 3 nM estradiol increased proliferation
2- fold. Figure 3.15b shows the effects of the 3 isomers on proliferation of a different estrogen-
responsive, breast cancer cell line, MCF7.  Relative to control cell numbers on day 6, p-
acetamidophenol increased proliferation 1.7-fold, m-acetamidophenol increased proliferation 1.4-
fold, while o-acetamidophenol had no effect on proliferation; estradiol induced proliferation 2.5-
fold.
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Figure 3.15 Effects of acetaminophen positional isomers on T47D (a) and MCF7 (b)
cell proliferation. Cells were treated as described in Figure 1 with 3 nM estradiol (E) or with: (a)
0.1 mM o-, m-, p-acetamidophenol (A) or (b) 0.3mM o-, m-, p-acetamidophenol (A). C indicates
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number of cells initially plated and receiving vehicle. After six days and two exposures to
acetaminophen or estradiol, cells were counted in a hemocytometer; C’ indicates number of cells in
cultures receiving only vehicle for 6 days; “*” indicates statistically significant differences from
control; “#” indicates statistically significant differences from estradiol.
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3.4 Acetaminophen Metabolism in Microsomal Preparations
The objective this study was to determine if acetaminophen metabolism could be detected
in breast cancer cell microsomes. The study of microsomes was necessary because when whole
cells were analyzed, no metabolites could be detected (Miller and Siegel, unpublished data). A
positive control in these experiments was Arochlor-induced rat S9. Non-induced human liver
microsomes were also tested. As anticipated, the cysteine-acetaminophen peak produced by the
metabolism of acetaminophen via the cytochrome P450 mediated path, eluted at 7.7 minutes and
was well resolved from the parent acetaminophen peak which eluted at 10.3 minutes (Zaher et
al., 1998). The limit of detection of the HPLC was 5 pmoles in 100 l sample injected into the
column. Figure 3.16 shows that the acetaminophen-cysteine conjugate was formed in greatest
amounts by S9 derived from Arochlor-induced rat liver samples. The acetaminophen-cysteine
conjugate was also formed by non-induced human liver microsomes but in lower amounts. In
MCF7 cell samples, the acetaminophen-cysteine (Ac-Cys) conjugate was not detected in samples
from cells treated with medium alone or with acetaminophen. However, the acetaminophen-
cysteine metabolite was detected in small amounts in microsomes prepared from MCF7 cells
induced with TCDD or BNF. The acetaminophen-cysteine metabolite was also formed by
microsomes from MDA-MB-231 cells pretreated with BNF or acetaminophen.
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Figure 3.16 Acetaminophen metabolites from breast cancer cells microsomes. Samples were
prepared and analyzed as described in methods. Rat=rat S9 induced with Arochlor;
Human=human liver microsomes, noninduced; 1=MCF7; 2=MDA-MB-231; C=control
microsomes from cells treated with estrogen-free medium; T=microsomes from 10nM TCDD
treated cells; B=microsomes prepared from cells treated with 40M beta-naphthoflavone; A=
microsomes from cells treated with 0.1 mM acetaminophen. Cell treatments were for 24 hours
(n=2 for MDA- MB-231 cells; n=1 for MCF7 cells).
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3.5 Tumor Growth
The goal of these studies was to assess the effects of acetaminophen on ER+, MCF7 tumors
in nude mice. Following the implantation of MCF7 cells in the breast fat pads of ovariectomized
nude mice, small tumors were observed. Relative to tumors in control animals, the tumors in the
ovariectomized nude mice treated with estradiol (E), estradiol + acetaminophen (E+A) and
acetaminophen (A) increased in size by day 36 as shown in Figure 3.17. However, all tumors
regressed to levels that could not be measurable on day 44.
Figure 3.17 Acetaminophen stimulates MCF7 tumor growth in nude mice by day 36.
Treatments are as described in the methods section.
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Because a previous study conducted by Cramer et al. (1998 b) indicated that
acetaminophen can affect plasma estradiol levels in women, plasma estradiol levels were
measured in this study as well. Samples from day 44 were collected and estradiol levels were:
control 11.6  0.2; acetaminophen 8.5  0.9; estradiol 155  31; estradiol + acetaminophen 166 
0 pg estradiol/ml.
92
3.6 Data Summary
Acetaminophen induces proliferation in ER+/PR+ breast cancer cells but not in ER-/PR+
or ER-/PR- breast cancer cells or in normal breast cells. A summary of the types of cells
stimulated by acetaminophen is shown below.
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These data indicate that acetaminophen-induced proliferation may involve ER. Further
support to this conclusion comes from studies showing that acetaminophen-induced proliferation
can be inhibited by antiestrogens. From this point of view, acetaminophen mimics estradiol.
However, acetaminophen does not compete with estrogen for binding to ER. From this point of
view, acetaminophen does not mimic estradiol. Another difference between acetaminophen and
estradiol is that acetaminophen is much less (105) potent (but pharmacologically relevant) than
estradiol. These conclusions are summarized in the table below.
 Where:  = inhibition.
ER Involvement
       Chemical    Acetaminophen    Estradiol
   Effect
        
Similarities
   Antiestrogen ?           yes       yes
    ER involved? yes                       yes
                   
Differences
   Sensitivity to ?        high          low
    (Acetaminophen vs Estradiol)
   ER binding?  no        yes
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Consequently, although acetaminophen and estradiol share some similarities in
stimulating ER+ breast cancer cell proliferation, the mechanisms by which these compounds act
appear different. In addition, acetaminophen metabolism is not detected in MCF7 breast cancer
cell microsomes unless cells are pretreated with TCDD or BNF.
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CHAPTER IV. DISCUSSION
Most studies of acetaminophen have shown that this drug has inhibitory and/or toxic
effects on various tissues and cells. A strong criticism, however, is that most in vitro studies
showing such inhibitory effects have been conducted at unrealistically high acetaminophen
concentrations, well above intoxication levels that would lead to death in humans. Many in vivo
studies that show inhibitory effects have also used doses of acetaminophen that are well above
intoxication levels in humans. Thus, it is important to place the relevance of such findings in
perspective. This report is novel and demonstrates that concentrations of acetaminophen
achieved in plasma following administration of pharmacological doses of acetaminophen
selectively stimulate estrogen-responsive human breast cancer cell proliferation. This conclusion
is based on the observation that acetaminophen stimulated proliferation in three different ER+
breast cancer cells but did not in two ER- breast cancer cells. The importance of testing multiple
ER+ and ER- cell lines is illustrated by the report that -sitosterol stimulates T47D but not
MCF7 breast cancer cell proliferation (Mellanon et al., 1996). Furthermore, using different breast
cancer cell lines is likely to more accurately represent the in vivo heterogeneity of cells.
The concentrations of acetaminophen used in this study reflect therapeutic and toxic
levels achieved in humans. The typical therapeutic adult dose of acetaminophen is 0.325-1.3 g
administered every 4-6 hours (Kastrup, 1981), resulting in plasma concentrations of
approximately 0.03-0.12 mM (Forrest et al., 1982). Doses over 10 g are toxic (Kastrup, 1981)
and lead to plasma concentrations of approximately 1 mM (Jensen et al., 1996).
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In addition to testing multiple ER+ and ER- cell lines, three different endpoints were
tested: 3H-dT incorporation into DNA, % S phase cells and cell numbers. These endpoints
provided consistent responses of ER+/PR+, ER-/PR+ and ER-/PR- cells tested to both
acetaminophen and estradiol. Concentrations of 0.1-0.3 mM acetaminophen stimulated 3H-dT
incorporation into DNA, % S phase cells, and cell numbers only in the ER+/PR+ cell lines. The
ER+/PR+ cell lines were similar in that they all exhibited acetaminophen- and estradiol-induced
proliferation. However, the magnitude of the acetaminophen- relative to the estradiol-induced
response varied somewhat in different experiments and among the different ER+ cell lines. Part
of this variation may be attributed to differences among endpoints measured and to inherent
differences among the three ER+/PR+ cell lines (distribution of receptor subtypes, origin of cell
lines, etc.).
These results suggest that ERs may be involved in mediating acetaminophen-induced
proliferation of ER+/PR+ breast cancer. In contrast, acetaminophen does not induce proliferation
of breast cancer cells that are ER-/PR- or of cells that are deficient in ERs but have high PR
levels. For example, acetaminophen does not induce proliferation in T47Dco cells. These cells
have PRA-PRB heterodimers and PRA and B homodimers; they also have low levels of wild
type and mutant ER’s. These data could be interpreted to mean that acetaminophen, like estradiol
may not bind to ER mutants that have alterations in the ligand binding domain (as in T47Dco
cells) and/or that ER levels are too small for a weak agonist such as acetaminophen to elicit any
estrogenic effects. In addition, since some inhibitory activity is displayed in T47DYB
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cells by acetaminophen at high concentrations PRB homodimers may be involved in
acetaminophen-induced inhibition of proliferation in these T47DYB cells. Second,
acetaminophen-induced proliferation of ER+/ PR+ cells is inhibited by both a pure antiestrogen,
ICI 182,780 and by a partial antiestrogen, 4’-hydroxytamoxifen. Our results are consistent with
other studies demonstrating that ICI 182,780 is a more potent inhibitor of estradiol-induced
proliferation than is 4’-hydroxytamoxifen (Osborne et al., 1995, Branham, 1996). ICI 182,780 is
also a more potent inhibitor of acetaminophen-induced proliferation than is 4’-hydroxytamoxifen
and acetaminophen-induced proliferation is more sensitive to ICI 182,780 inhibition than is
estradiol-induced proliferation. These results support a role of ERs in mediating acetaminophen-
induced proliferation.
On the other hand, acetaminophen does not compete with estradiol for binding ERs in
MCF7 cells. Collectively, these data suggest that acetaminophen- and estradiol-induced
proliferation of breast cancer cells both involve ERs. However, while estradiol binds ERs,
acetaminophen does not bind to the same site to which estradiol binds in the type of assays
conducted in these studies. The ERalpha rather than indicating a pathway of acetaminophen
action may instead represent a “biomarker” of cell types that may undergo acetaminophen-
induced stimulation of proliferation. Alternatively, the ERalpha requirement for acetaminophen
stimulatory effects may indicate an indirect pathway. Antiestrogens inhibit not only the ERs
directly but also some growth factors and their receptors (e.g., TGFalpha) while stimulating
growth inhibitory factors and their receptors (e.g., TGFbeta); these factors exert autocrine effects
on ER+ cells (Katzenellenbogen et al., 1997). Thus, the antiestrogen inhibition of
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acetaminophen-induced proliferation in ER+ breast cancer cells may mean that such growth
factors may be directly involved while ER may be only indirectly involved in the mechanism of
acetaminophen action. Examples of substances that do not directly bind to ERs but influence ERs
indirectly and ultimately lead to proliferation of breast cancer cells include environmental
compounds such as o, p’-DDT, and endogenous compounds such as growth factors and
neurotransmitters (Katzenellenbogen, 1997; DeCupris and Favoni, 1997; Smith, 1998; Enan and
Matsuma, 1998). In addition, this alternative, ligand-independent mechanism of proliferation that
does not involve direct binding of ligand to ERs usually involves modulation of kinases and/or
phosphatases by estrogens/antiestrogens. For example, epidermal growth factor does not directly
bind to ERs to stimulate proliferation of breast cancer cells. Instead, EGF binds its own plasma
membrane receptors, event that subsequently leads to activation of the MAPK cascade that
ultimately influences the transcriptional activation of ER and proliferation of some ER+ cells
such as breast cancer cells (Smith, 1998). Other compounds can stimulate other kinases such as
protein kinases A (PKA) and C (PKC) or tyrosine kinases (TK) and such compounds lead to
stimulation of proliferation of breast cancer cells. Conversely, compounds that inhibit kinases
such as PKC (e.g.,  tamoxifen) inhibit proliferation of breast cancer cells (DeCupris and Favoni,
1997, Katzenellenbogen, 1997). In addition, compounds such as okadaic acid stimulate
proliferation of breast cancer cells by inhibiting protein phosphatases (Smith, 1998). Thus,
acetaminophen may modulate proliferation of breast cancer cells by modulating
kinases/phosphatases. In fact, from a mechanistic standpoint, acetaminophen may mimic growth
factors rather than estradiol in ER+ breast cancer cells and estradiol may not be the best model
for acetaminophen in these cells.
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In summary, it is possible that acetaminophen may alter breast cancer cells by altering
Hsp90-ER interaction, ER conformation, ER phosphorylation status, kinases or phosphatases
activity or levels, and/or ER cofactor/regulator levels/availability. In alternative pathways,
estradiol upregulates some growth factors and their receptors, leading to autocrine stimulation of
proliferation; some antiestrogens inhibit this pathway (DeCupris and Favoni, 1997).
Acetaminophen may act indirectly via such a pathway that crosses the ER pathway. A simplified
representation of the mechanisms by estradiol, xenoestrogens, and growth factors may induce
proliferation in ER+ cells is shown below.   
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Where:
E = estradiol/estrogens
X = xenoestrogens
ER = estrogen receptors
GF = growth factors
NT = neurotransmitters
ER-P = phosphorylated estrogen receptors
   Mechanisms
of Estrogen and Xenoestrogen Action
 I. Classical                                                 II. Alternative
                 E/X                                                                                 E/X
                                E/X-ER              ER       ~cAMP          GF/NT
  Proliferation
                       DNA             DNA            ER--P
              
  

 DNA synthesis     TyrK
                                                                       2nd
                                                              messengers
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TyrK = tyrosine kinases/kinases
It would possible to test the involvement of some of these alternative pathways or
components of these pathways in acetaminophen-induced proliferation. For example, similar to
the experiments in which antiestrogens were used to test for the involvement of ERs in
proliferation, one could test for the involvement of phosphorylation. The effects of tyrosine
kinase and mitogen activated protein kinase (MAPK) inhibitors, such as geldanamycin on
acetaminophen-induced breast cancer cell proliferation could be established. The effect of protein
phosphatase inhibitors, such as okadaic acid, on acetaminophen-induced proliferation of breast
cancer cells could also be established. Inhibition of proliferation by protein kinase inhibitors
would suggest involvement of protein kinases in acetaminophen-induced proliferation. Inhibition
of proliferation by protein phosphatases would suggest involvement of protein phosphatases in
acetaminophen-induced proliferation.
There are clear similarities, as well as differences, between breast cancer cell proliferation
induced by acetaminophen and 17 -estradiol. There are major similarities between
acetaminophen- and 17 -estradiol-induced proliferation. These include: (1) both compounds
induce proliferation in ER+/PR+ human breast cancer cells with high ER levels; (2) neither
compound induces proliferation in breast cancer cells with low ER and high PR levels or in ER-
/PR- breast cancer cells; and (3) both compounds induce proliferation that is inhibited by
antiestrogens. Thus, from this perspective, acetaminophen acts like an estrogen. Differences
between acetaminophen and 17 -estradiol include: (1) effects on cells other than breast cancer
cells (e.g., fish liver cells where estrogen has estrogenic activity while acetaminophen has
102
antiestrogenic activity); (2) potency of these compounds in inducing proliferation in breast cancer
cells; and (3) mechanism of breast cancer cell proliferation induction.
This study shows that T47D and MCF7 breast cancer cells undergo proliferation in
response to p-acetamidophenol, the isomer found in medication. The relative potency of the 3
acetamidophenol isomers is p > m > o  control. The fact that the positional isomers of
acetaminophen (m- and o-acetamidophenol) were less potent than acetaminophen (p-
acetamidophenol) suggests that the –OH position on the benzene ring is an important element
within the chemical structure of acetaminophen that determines the extent to which proliferation
is induced in the studied system. These findings are consistent with previous studies that have
shown p-phenols have estrogenic activity and are more potent proliferation inducers in cultured
breast cancer cells than their m- and o-isomers (Soto et al., 1991).
Acetaminophen appears to have estrogenic effects in one system, e.g., increasing
proliferation in ER+ human breast cancer cells (Harnagea-Theophilus and Miller, 1998) . On the
other hand, acetaminophen has antiestrogenic effects in another system, e.g., decreasing
vitellogenin production in trout liver cells (Miller et al., 1999) or has no estrogenic effects in
other systems, e.g., no increase in rodent uterine weight (Harnagea-Theophilus et al., 1999).
Thus, acetaminophen displays a spectrum of effects from stimulation to inhibition of various
estrogenic responses. These findings are consistent with other reports in which a single
compound was found to exert estrogen agonistic or antagonistic effects depending on the species
and tissue on which it acts. For instance, betulin and pinosylan elicit estrogenic effects
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in human breast cancer cells but not in trout liver cells (Mellanon et al., 1996) while raloxifene
exhibits antiestrogenic effects in human breast but estrogenic effects in human bone (Penissi,
1997).
First, these observations suggest that acetaminophen mimics some of estradiol effects,
and this mimicry is cell-type specific or selective. Second, like many other exogenous
compounds with selective estrogenic action, acetaminophen is 105 less potent than estradiol in
inducing proliferation in breast cancer cells. Although acetaminophen is much less potent than
estradiol, the concentrations that stimulate breast cancer cell proliferation are pharmacologically
relevant. Third, the mechanism of acetaminophen-induced proliferation appears to be different
from that of estradiol-induced proliferation. While estradiol binds ERs in MCF7 cells,
acetaminophen does not. Similar patterns of differences in effects and mechanisms of action
between estradiol and other estrogenic phenols, such as bisphenol A, have recently been reported
(Gould et al., 1998). For example, unlike estradiol, bisphenol A had no effect on uterine weight;
however, like E2, it induced PR levels, though not to the level induced by estradiol. Thus, many
of the compounds that are lately found to mimic estrogen action, mimic this action selectively or
partially, not totally, depending on the tissue studied and the endpoint monitored.
The variety of effects acetaminophen exerts in different estrogen-responsive tissues may
be attributed to differences in distribution of estrogen receptors subtypes in different tissues;
differences in acetaminophen concentrations used in different studies; differences in metabolism
in different tissues; and/or differences in species (human, rodent, fish) used in
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different studies. Indeed recent findings of other ER subtypes help interpret such apparently
paradoxical effects. For example, MDA-MB-231 breast cancer cells were shown to be ER-
/ER+ cells and in these cells both wild type and variant ER (exon 5 deleted; impaired hormone
binding domain function) are present. If it is assumed that acetaminophen acts via ER’s at all,
then in order for it to elicit estrogenic effects at least in breast cancer cells, it may need either
only ER  present (as in ZR-75-1 cells) or a mixture of ER  and  hetero/homodimers in which
    (as in MCF7 or T47D cells).
It is noteworthy that many systems inhibited by acetaminophen contain ER . The
antiestrogenic effects of acetaminophen may be mediated by this receptor subtype in cells with
only the  subtype or in which  is predominant over . For example, trout ER is an analogue of
human ER, and ER in ovaries are mainly  (with human granulosa cells only ). By contrast,
normal breast tissue and ER+ breast cancer tissue, with some exceptions, usually has ER   
(Enmark et al., 1997). Moreover, the ER subtype in breast appears dependent on ER but not
vice versa, because in ER- mice, the breast is absent (thus both  and ) while ER- mice
develop normal breasts. The breast, thus, may have its unique ER- interactions, different from
other reproductive organs but consistent with its own function.
Acetaminophen appears stimulatory to initial stages of MCF7 tumor growth in
ovariectomized nude mice. However, it must be understood that this was only a preliminary
experiment that needs to be validated. The main problem with the in vivo experiment was that
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most tumors regressed (including the positive controls) by day 44. This could have been due to
improper inoculation/pellet implant in some of the mice, although all tumors developed initially.
Alternatively, although these mice are immunospuressed, the suppression is not total but partial.
In fact these mice have more natural killer cells than normal mice of similar backgrounds do.
Thus, it is possible that the tumors regressed partly because of the involvement of the remaining
immunity.  In addition, since this experiment was done once, no clear conclusions can be drawn
regarding this effect in vivo. It is possible that acetaminophen may initially stimulate and then
inhibit tumor growth, if this experiment is reproducible.
The nude mice study also indicates that acetaminophen may affect estradiol levels in vivo.
Estradiol levels were reduced from 11.6  0.2 pg/ml in controls to 8.5  0.9 pg/ml in
acetaminophen-treated mice,  indicating  that acetaminophen may lower estradiol levels produced
by tissues other than ovaries. These findings are consistent with a recent report (Cramer et al.,
1998 a, b) that estradiol levels were significantly reduced by acetaminophen in women over 34
years of age. Cramer et al., 1998 a, b suggested that this characteristic of the estradiol-
acetaminophen interaction might offer protection against estrogen-dependent cancers in humans.
It was not possible to detect acetaminophen metabolism in microsomes form MCF7 cells
unless cells were pretreated with TCDD or with BNF to induce cytochrome P450. Although the
metabolism of acetaminophen is not detectable in this assay in the absence of induced
cytochrome P450, we cannot say that it is unimportant. It remains to be determined whether the
parent compound or a metabolite of acetaminophen causes proliferation in
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ER+/PR+ breast cancer cells. It would be easy and logical to test the effects of  acetaminophen
metabolites directly on proliferation. Unfortunately, these metabolites are not commercially
available, thus, such experiments could not be conducted.
In vivo, there are 2 major pathways involved in the metabolism of acetaminophen (see
next figure). There is a detoxification pathway (involved when therapeutic doses of
acetaminophen are administered) and a toxication pathway (involved when toxic doses of
acetaminophen are administered and detoxication pathways are saturated).
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In the detoxication pathway, paracetamol metabolizes into readily excreted compounds.
In most species, glucuronide and sulfate metabolites are major metabolites, constituting 70-90 %
of the total conjugates excreted (Prescott, 1996), while cysteine and mercapturic acid conjugates
are minor metabolites. In addition, approximately 3 % of the parent compound is excreted
unchanged. Formation of glucuronide conjugates is catalyzed by glucuronosyl transferases while
formation of sulfate conjugates is catalyzed by sulphotransferases (Prescott, 1996). Sulphate
conjugation is a major, parallel route of detoxication, inversely correlated with glucuronide
conjugation. The enzymes catalyzing the sulfation reaction include cytosolic, ubiquitous aryl
sulphotransferases and, depending on the concentration of
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paracetamol used, different enzyme isoforms are involved in catalysis (Prescott, 1996).
Glutathione-S-transferase catalyzes the formation of m-GSH conjugates and the resulting
metabolites are almost exclusively excreted into bile. Paracetamol has low affinity for GSH
conjugation, and the process is not readily saturated even at high concentrations (10-25 mM or
1500-3800 mg/l) (Prescott, 1996). Regarding the distribution of GSH conjugates, concentrations
of GSH metabolites in tissues other than liver are very low.
The percent glucuronide formed in various species spans a broad range. Glucuronide
metabolites comprise 50-60% of dose in man while 25-35 % of acetaminophen is metabolized to
sulfate conjugates (Prescott, 1996). In humans, small oral doses of paracetamol (< 40 mg/kg) can
lead to excretion of ~11 % as cysteine and mercapturic acid conjugates and the paracetamol
cysteine conjugate is 2-5% in man (Prescott, 1996). However, the relative percentage of
glucuronide and sulphate conjugates varies greatly with many factors, including dose magnitude,
dosing regimen, age, animal strain, gender, concomitant drug use (e. g., oral contraceptives),
lifestyle (e.g., smoking), and disease state (e.g., glucuronosyl transferase deficiency states as in
Gilbert’s diseases).
The intoxication pathway is activated when toxic doses of paracetamol are administered.
In that situation, glucuronidation, sulfation, and glutathione conjugation cannot keep up with the
high dose of drug that needs conjugated. Glutathione (GSH) is consumed increasingly and when
levels fall under 20-40 % of total glutathione, then the GSH pathway cannot effectively detoxify
the excess of intermediary reactive metabolite formed. The reactive metabolite
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arylates cell macromolecules instead of conjugating with GSH, leading to toxic effects especially
in paracetamol target organs that accumulate high concentration of paracetamol, the liver and
kidneys. The intermediate, N-acetamidoquinone, can function as both an oxidant and an
electrophile (Miners and Kissinger, 1979). The intermediate is moderately stable and can react
with nucleophiles (cysteine, N-acetylcysteine, GSH) to reversibly form paracetamol or the
corresponding thiol adducts (Dahlin, 1984). Spontaneous reactions lead to formation of the
glutathione conjugate, paracetamol, and GSH.
Is it plausible that acetaminophen conjugates may stimulate proliferation of breast cancer
cells in vivo? Metabolites such as glucuronide and sulfate conjugates are large and much more
hydrophilic than the parent compound, so that, in vivo, they facilitate excretion of
acetaminophen. In addition, the p-phenol was shown to play a role in proliferation of ER+ breast
cancer cells. If that is the case, then one would not expect the glucuronide and sulfate conjugates
to impact proliferation because in that case, the hydrogen in the phenol moiety is actually
substituted for a different group (-OH =>-Oglucuronide/-Osulphate).  A recent study supports
this statement. Tabira et al., 1999, have shown that while phenol itself has weak estrogenic
activity, p-nonylphenol has maximal estrogenic activity;  however, compounds that such as
anisole, that have a substituted phenolic group have no estrogenic activity. As for the metabolites
formed via NAPQI, they would have relatively bulky substituents in the m-position and we and
others have shown that such position of a substituent does not favor proliferation (Tabira et al.,
1999; Cunningham et al., 1997, Anstead et al., 1997). The only potential metabolites that may
influence proliferation would be small, hydrophobic molecules that could diffuse
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across cell membranes. These may include the NAPQI or the deacetylated metabolite, p-
aminophenol, but the latter metabolite is not formed in humans, only in animals (Prescott, 1996).
Thus, it appears most likely that the parent compound is responsible for proliferation of breast
cancer cells in vivo.
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Possible Implications
Most of these studies were conducted in vitro. Given that the in vivo experiment was not
conclusive, it is difficult to extrapolate the observed effects to comment on implications for
humans. More in vivo data are necessary before one could conclusively state whether these
effects of acetaminophen are detrimental, beneficial or insignificant (an in vitro artifact). The
data are limited and extrapolations are complex. If, however, one speculated on the implications
of these data, then there are two scenarios worth pointing out. The first is: if acetaminophen turns
out to stimulate tumor growth in animals and/or ultimately in humans, then acetaminophen use
may impact postmenopausal women with undetected breast tumors of the ER+/PR+ type who
take acetaminophen frequently. These women may potentially experience tumor growth.
Conversely, acetaminophen may ultimately inhibit ER+/PR+ tumors, because it may lower
circulating estradiol levels, as Cramer et al. (1998 a, b) suggested. This effect may be especially
relevant when estrogen levels are high, such is the case in premenopausal women or women on
contraceptives or women on estrogen replacement therapy. In that case, acetaminophen
consumption may be beneficial, leading to tumor inhibition.
Some potential experiments that may help elucidate the important question of the effects
of acetaminophen in vivo are mentioned below. Since under proper experimental conditions
tumors can be maintained in nude mice for more than 2 months (Clarke, 1996), repeats of the
nude mice experiments could provide conclusive information regarding the long-term effect of
acetaminophen on ER+ breast cancer tumors. Acetaminophen and estradiol implants could be
used in this case. The advantage of this type of experiment is that one would study
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the effects of acetaminophen on the same cells on which we observed the effects in vitro, thus,
the experiments may have a good chance of producing conclusive results. Alternatively, tumors
could be induced easier and faster with a known cancer inducer, such as dimethylbenzanthracene,
then acetaminophen could be administered to determine if it stimulates tumor growth. However,
in this case, the tumor is not of human origin, so the relevance is to some extent diminished.
Nevertheless, such experiment would provide information regarding the potential of
acetaminophen to induce or inhibit tumor growth.
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Conclusions
These studies provide novel information about acetaminophen effects on breast cancer
cells, and conclusions drawn from these studies are indicated below. First, acetaminophen can
induce in ER+ human breast cancer cells in vitro proliferation, similar to that induced by
estradiol. Second, the mechanism by which acetaminophen-induced proliferation occurs is not
clear. It is clear, however, that whatever the factor on which acetaminophen acts, that factor is
present in ER+ cells while it is absent form the ERalpha- cells. The stimulatory effects induced
by acetaminophen occur only in the ER+ cells that were tested. In order for acetaminophen to
elicit effects in these cells, they must have either ERs or some other receptors that perhaps are
present in all the ER+ cells studied but not in ER- human breast cancer cells. An alternative
interpretation would be that perhaps acetaminophen may require not the ER itself but instead
some factors/proteins associated with it such as the Hsp90 heterocomplex. Alternatively,
acetaminophen may affect some enzymes involved in proliferation that may be present in ER+
but may be absent in ER- cells. Yet another possibility may be that acetaminophen may affect
some growth factors involved in proliferation of ER+ breast cancer cells. In either of these cases,
the mechanism of acetaminophen-induced proliferation appears to differ from that of estradiol, at
least based on results from the whole cell assays where no ER binding was detected.
Another clear conclusion is that the potency of acetaminophen in stimulating ER+ human
breast cancer cell proliferation is much lower than that of estradiol, yet the effective
concentration of acetaminophen is pharmacologically relevant. As for acetaminophen metabolites
in the ER+ cells or their microsomes, it is possible that metabolism may occur in ER+
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cells but if metabolites form at all, they are minimal and thus undetected by the HPLC method
tried. The possibility exists that metabolites of acetaminophen could be involved in proliferation
even if they cannot be detected. However, it appears more likely that parent acetaminophen is
responsible for the stimulation of proliferation observed in ER+ breast cancer cells in vitro.
Overall, these studies contribute to a better understanding of acetaminophen interaction with
breast cancer cells in vitro, a research area largely unstudied.
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